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Summary 
 
Background: Currently, it is not possible to predict disease behaviour for children with inflammatory 
bowel disease (IBD), which is a major obstacle in an era where we strive to deliver personalised, 
tailored therapy. Previous investigation of gene expression profiles from CD8+ T-cells in adult IBD 
cohorts identified promising signatures, including a T-cell exhaustion signature, to predict disease 
outcome in these patients.  
Hypothesis and aim: We hypothesised that adult CD8+ T-cell prognostic signature and T-cell 
exhaustion signature would also predict outcome in paediatric IBD. We also hypothesised that CD8+ 
methylation profiles would underpin changes in gene expression, hence providing an alternative 
potential predictor. The aim of this project was to test whether CD8+ T-cell gene expression and 
methylation signatures can predict disease outcome in children with IBD.  
Methods: Purified CD8+ T-cells from a prospective cohort of 112 children newly diagnosed 
(treatment naïve) with IBD were subjected to cellular genome-wide RNA and DNA profiling 
(affymetrix and epic methylation microarrays). Detailed clinical information from each patient was 
recorded in a clinical database (1.5 years follow-up). First, the adult CD8 prognostic signatures were 
applied to the paediatric data in order to test for their ability to differentiate children according to their 
disease behaviour. Subsequently, the paediatric data was analysed on its own through unsupervised 
clustering analysis and Weighted Gene Co-expression Network Analysis (WGCNA) to test for 
correlations between gene expression data and clinical outcome parameters. Survival analysis 
(kaplan meyer) was used to compare patient groups for disease outcomes, including number of 
treatment escalations, use of biologic treatments and surgical intervention. 
Results: Applying the adult CD8 prognostic signature and the T-cell exhaustion signature to the 
paediatric dataset did not generate groups with significant differences in disease outcomes. 
Furthermore, the clinical data collected from the paediatric cohort showed that two thirds of the 
children had at least two treatment escalations, compared to less than 40% of the adult patients from 
the previous study. The analysis of the paediatric data per se identified correlations with clinical 
outcomes including use of biologics in Crohn’s (WGCNA correlation index (CI) < 0.4) and surgical 
intervention in ulcerative colitis (top CI: +0.38 and – 0.59). Preliminary analysis of the CD8 
methylation profile did not show any correlation with clinical outcomes in this paediatric cohort. 
Conclusion: The adult prognostic CD8 signatures did not prove to be effective in children with IBD. 
We speculate that this could be due to the paediatric IBD phenotype being homogeneously more 
severe. Our findings hint the hypothesis that absent T-cell exhaustion in paediatric CD8+ T-cell could 
underlie a more severe disease phenotype in children. Further understanding of the mechanism of 
T-cell exhaustion in children has the potential to open up to future target options in paediatric IBD. 
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1.1 Paediatric inflammatory bowel disease (IBD) 
 
The term inflammatory bowel disease (IBD) covers a heterogeneous group of chronic disorders of 
the digestive tract, causing relapsing inflammation of the intestinal mucosa. The two main entities in 
IBD are Crohn’s disease (CD) and ulcerative colitis (UC). While in UC the inflammation is generally 
restricted to the mucosa of the large bowel, CD can spread throughout the entire gastrointestinal 
(GI) tract and affects all layers of the bowel wall (i.e., trans-mural inflammation). A third entity 
describes patients whose diagnostic features do not fully qualify for either CD or UC and are 
therefore diagnosed with IBD-unclassified (IBD-U) 1,2. In IBD, the disease onset can range from early 
childhood to beyond the sixth decade of life, and over the past few decades there has been a 
significant increase in the incidence of this condition 1. This increase has been particularly noticeable 
in children and young adults, who currently constitute almost 30% of all patients diagnosed with IBD 
3-6. In the absence of any curative treatment, patients are faced with a lifelong, often severely 
disabling condition.  
Managing IBD in children is particularly challenging for several reasons such as body growth, puberty 
and the need to attend school during a crucial phase of their lives. Growth failure and impaired 
nutritional status are seen in 65-85% of children and adolescents diagnosed with CD, and 15-40% 
of these patients continue to suffer from growth deficiency throughout the course of their disease 7,8. 
Delayed growth may precede any clinical evidence of bowel disease, and can severely affect the 
quality of life of children and adolescents with CD 9-12. Because of its relevance to the care of children 
with IBD of developmental age, growth assessment was included in the Paris classification of 
paediatric CD, which replaced the previous Montreal classification 13.  
 
1.2 Epidemiology of IBD 
 
The incidence of IBD is increasing worldwide, and over the past few decades, advances have been 
made in understanding its evolving epidemiology. This rising pattern may be due to improvement in 
disease detection and recognition, as well as environmental alterations and exposure that impact 
the disease onset. IBD was once considered to be a “Western” disease, principally affecting patients 
in North America and Western Europe, but it is now clear that the incidence and prevalence of this 
condition are both rapidly rising in other parts of the world, with dramatic increases noted in India, 
Japan, China, and the Middle East 14. IBD is, in fact, emerging in previously low-prevalence areas 
such as the developing world, as well as among migrant populations moving to industrialised 
westernised countries 14-16. (Figure 1.1) 
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Figure 1.1 Global map of IBD in established and emerging populations. (Taken from: Cosnes J, et al. 
Gastroenterology 2011 16) 
 
The changing epidemiology of IBD across time and geographies (north-south and west-east 
gradients) suggests that environmental factors play a major role in modifying disease expression, 
and its rising incidence in developing societies seems to be linked to industrialisation and the 
Western lifestyle 14-19. Individual, familial, community-, regional- and country- based environmental 
risk factors could, in isolation or in association, contribute to IBD’s pathogenesis. Urbanisation in 
developing countries, diet changes, antibiotics, hygiene status, microbial exposure and pollution 
have all been implicated as potential environmental risk factors for IBD 20,21. 
The geographical variability in IBD incidence and prevalence may, in turn, reflect a variety of 
underlying genetic patterns in different populations 20. The current mean prevalence of IBD in the 
general population of Western countries is estimated at 1/ 1,000 inhabitants 22,23. IBD primarily affects 
the Western world and the highest incidence rates are observed in North America and Europe 17, 24-
26. Recent studies in the UK indicate that the incidence of paediatric IBD is 5.2 per 100,000, where 
3.1 of those cases are CD, 1.4 are UC and 0.6 are IBD-U 27. Although there is limited epidemiology 
data available regarding developing countries, the incidence and prevalence of this disease have 
both been increasing over the past 50 years in practically all regions of the world, indicating its 
emergence as a global disease 14,28. The trend appears to have stabilised in the adult population but 
not in children, especially in central and southern Europe where it still appears to be rising 17,18. 
Incidence and prevalence of childhood-onset IBD has almost doubled over the last decade, and 
children currently constitute almost 30% of all patients diagnosed with IBD 14,28. Patients can be 
diagnosed with IBD at any age, but peak incidences are observed in childhood (between 10-15 years 
of age) and early adulthood (i.e., the second to third decades of life) 17,18,29,30. Estimates of the 
incidence of paediatric-onset IBD reported around the world vary considerably 31 as do its patterns 
and distributions in the various age brackets of the paediatric population 32,33.  
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The disease distribution by gender shows a slight male preponderance (1.5:1) in CD patients before 
puberty, whereas a female preponderance is reported in adults 34-36. While initially relatively low, CD 
incidence has gradually risen to levels that are similar to those of UC 16. CD incidence rates seem to 
have been stable in most industrialised countries since the 1980s, whereas an increase in childhood-
onset IBD continues to be observed 37-39. 
Accordingly, this disease represents an increasing burden upon global health, which is likely to 
continue to grow in the future. 
 
1.3 Current models of IBD pathogenesis 
 
The molecular patho-physiology of IBD remains largely obscure. Experimental studies and genetic 
evidence suggest that chronic intestinal inflammation is triggered by various environmental factors 
in genetically susceptible individuals. During the last decade, several genome-wide linkage and 
association studies have revealed over 200 genetic polymorphisms associated with an increased 
susceptibility to CD and UC 40-45. (Figure 1.2) 
 
 
Figure 1.2 Mutations in genes implicated in the pathogenesis of IBD regulate various biological functions such 
as immunomodulation, mucosal barrier integrity and microbial homeostasis. (Taken from: Lees CW et al. Gut 
2011. 44) 
 
Major efforts have focused on investigating the role of genetic factors in IBD pathogenesis. A number 
of disease-predisposing genetic variants (i.e., Single Nucleotide Polymorphisms (SNPs)) have been 
identified, but these can, at best, explain up to 30% of IBD cases 46,47, which suggests that other 
factors make a substantial contribution to IBD pathogenesis. 
Genes that are implicated in the pathogenesis of IBD regulate various biological functions such as 
immunomodulation, mucosal barrier integrity and microbial homeostasis 48,49.  
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However, despite extensive research in the field of adult and paediatric IBD using increasingly 
sophisticated tools, our understanding of disease pathogenesis remains incomplete for the majority 
of cases. Hence, the most widely accepted general hypothesis to explain the development of IBD 
continues to include three main factors: genetic predisposition, environmental influences and the 
homeostasis between the intestinal microbiome and host immunity 50 (Figure 1.3). The complex 
interaction of these factors is ultimately considered to cause chronic relapsing inflammation of the 
intestinal mucosal lining and the well-described phenotypes.  
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Interaction of various factors contributing to chronic intestinal inflammation in a genetically 
susceptible host. (Taken from: Sartor BR, et al. Nature Clinical Practice Gastroenterology & Hepatology 
2006.50) 
 
In the absence of a major genetic factor, the environment has moved back into the focus of 
researchers as the possible main causative factor. Epigenetics can be defined as heritable changes 
to phenotype (e.g., gene expression) that are due to mechanisms other than changes to the 
underlying DNA sequence. These mechanisms operate at the interface between environmental 
stimuli and long-lasting molecular, cellular and even behavioural phenotypes that are acquired during 
periods of developmental plasticity 51,52. The study of epigenetic mechanisms in IBD aims to address 
questions currently unanswered about the processes mediating the effects of environmental factors 
on the intestinal mucosa. Unlike our genetic code, which remains stable throughout life, epigenetic 
profiles are influenced by exposure to environmental factors (e.g. smoke), diet or even behaviour. 
Nevertheless, as such environmentally induced epigenetic changes are passed on during cell 
division, they can ultimately determine a newly acquired phenotype in offspring 53,54.  
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Epigenetics could therefore provide the missing link in explaining clearly heritable complex, but non-
Mendelian, diseases such as IBD. To date, DNA methylation is amongst the best-studied of all 
epigenetic mechanisms and describes the enzymatic addition of a methyl group (CH3) to the fifth 
position of cytosine, forming 5-methylcytosine (5mC) 55. DNA methylation plays a role in regulating 
gene expression; in particular, it is thought to target regulation sites and make them inaccessible in 
direct or indirect ways 56. In mammals, cytosine methylation is not equally distributed across the 
genome but occurs mainly at CpG dinucleotides. The abbreviation CpG, standing for 5’-cytosine-
phosphate-guanin-3’, describes the linear sequence of a cytosine base followed by a guanine base, 
bound together by a phosphodiester bond. Overall, CpG dinucleotides are rare in the human genome 
but they are known to cluster together in so called CpG islands. CpG islands are often found in close 
proximity to the promoter region and the transcription start site of a gene and are mostly 
unmethylated 57,58. 
Aberrant DNA methylation patterns have been associated with numerous pathologies, including 
autoimmune, metabolic, and neurological disorders, as well as cancer 59-63. 
In support of the role played by epigenetic mechanisms, and DNA methylation in particular, in 
paediatric IBD, recent work has identified alterations in the DNA methylation profile of intestinal 
epithelial cells purified from children that are newly diagnosed with IBD, compared to those of control 
cells 64. Moreover, disease specific changes in DNA methylation and transcription patterns of the 
intestinal epithelial cells have been described in patients with CD and UC. These changes appear to 
be stable over time and correlate with disease outcome parameters 65. 
In conclusion, within a plausible model for disease pathogenesis in IBD, epigenetics may represent 
one of the major underlying mechanisms that mediate the effect of genetic predisposition, 
environmental triggers and the intestinal microbiome.  
 
1.4 T-cell subsets and their role in IBD pathogenesis 
 
T-cells play a central role in cell-mediated immunity. They are produced in the thymus where they 
mature from thymocytes. T-cells are distinguished from other lymphocytes by the presence of a T-
cell receptor (TCR) on their surface.  
Effector T-cells promote an active immediate response to a stimulus. The response involves helper 
T-cells, killer T-cells, and regulatory T-cells. At the opposite end of the spectrum, memory T-cells are 
longer lived to target future infections as necessary. 
Memory CD8+ T-cells that circulate in the blood and are present in lymphoid organs embody features 
of both naïve and effector cells (Figure 1.4). It is still debated whether memory T-cells develop from 
effector cells through a process of dedifferentiation or directly from naive cells 66. 
Previous studies show that when memory T-cells are generated after antigen exposure, the more 
activated T-cells become in response to an antigen (reflected in the “clonal burst” size), the more 
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memory T-cells are subsequently formed 67.  
Helper T-cells (CD4+) assist other processes, including differentiation of B-cells into plasma cells 
and activation of cytotoxic T-cells and macrophages. Helper T-cells are activated through 
presentation of a peptide antigen by MCH class II molecules, expressed on the surface of antigen-
presenting cells (APCs). Once activated, they secrete cytokines that mediate the active immune 
response.  
Cytotoxic T-cells (CD8+) destroy virus-infected cells and tumor cells, and are also implicated in 
transplant rejection. These cells operate by binding to antigens presented by MCH class I molecules. 
Memory T-cells include central memory T-cells (CD45+, CCR7+ and CD62L+), commonly found in 
the lymph-nodes and in the peripheral circulation, and effector memory T-cells (CD45+, CD44+, 
CCr7- and CD62L-) that lack of lymph node-homing receptors and are mainly found in the peripheral 
circulation and tissues. 
Regulatory T-cells are crucial for the maintenance of immunological tolerance, by terminating the T-
cell immune response toward the end of an immune reaction. They comprise two major classes, 
FOXP3+ and FOXP3-. 
Natural killer T-cells link the adaptive immune response to the innate immune system through 
recognition of antigens presented by CD1d and activation of functions related to both helper T-cells 
and cytotoxic T-cells. 
 
 
 
Figure 1.4 The differentiation of CD8+ T-cells and different CD8+ subsets. TN, naive T-cells; T SCM, stem 
cell memory T-cells; T CM, central memory T-cells; T EFF, effector T-cells; T EM, effector memory T-cells. 
(Taken from: Golubovskaya V, Wu L. Cancers 2016. 68) 
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Both CD4+ and CD8+ are known to play a role in the pathogenesis of IBD 69,70.  
Immune responses in the intestine are regulated in a way that allows protective immunity against 
pathogens, while limiting responses to dietary antigens and commensal gut flora 71. The gut-
associated lymphoid tissue acts as a “mucosal firewall” by preventing systemic dissemination of 
pathogens. Dendritic cells drive regulatory T-cell differentiation in response to dietary antigens and 
commensal bacteria. Although this process can be beneficial during homeostasis, recent evidence 
from animal studies suggests that tolerance to commensal-derived antigens may be lost during 
pathogen-induced epithelial damage and subsequent transient exposure to commensals, causing 
deranged responses to commensals and promoting inflammatory conditions, such as IBD 71. 
In addition to activated effector CD8+ T-cells being detectable in the mucosa of patients with IBD, 
several animal models 72,73 have identified in the destruction of intestinal epithelial cells by CD8+ T-
cells the primary event leading to the loss of barrier function and exposure to microbial antigens. 
Based on this evidence, it has been speculated that CD8+ T-cells may play an early role in triggering 
IBD whilst CD4+ T-cells would play a secondary role in the disease pathogenesis. 67 
Recently, using transcriptional signatures from CD8+ T-cells separated from patients with 
autoimmune conditions including systemic lupus erythematosus (SLE), vasculitis (AAV) and IBD, 
researchers were able to separate patients into different prognostic groups 67,74. These groups 
differed in gene expression within the IL-7 and TCR signaling pathways, including CD28 co-
stimulation and IL-2 signaling. These pathways are implicated in T-cell activation and the subsequent 
development of antigen-specific T-cell memory. Moreover, IL-7 signaling facilitates the survival and 
differentiation of effector cells into long-lived antigen-specific memory cells (through Bcl2 family-
mediated inhibition of the pro-apoptotic effects of Bim22) 67,74. 
This data stands in support of a role for CD8+ T-cells in determining the disease course of IBD. 
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1.5 Clinical presentation and diagnostic work-up 
 
The clinical presentation of childhood IBD is highly variable and symptoms can be subtle. However, 
there are a number of classical symptoms and, most importantly, some red flags that may indicate 
the presence of IBD in children and warrant further investigations.  
Symptoms of CD commonly include chronic diarrhoea (i.e. longer than 6 weeks), abdominal pain 
and/or weight loss. Unexplained anaemia and growth failure in children are red flags and therefore 
should be investigated further. Similarly, blood and/or mucus in the stool may be seen in up to 40-
50% of patients with CD and always requires further investigations 20. Perianal fistulas are present 
in 10% of patients at the time of diagnosis, and may be the presenting sign of CD 20.  
Extra-intestinal manifestations (EIMs) are seen in 10-20% of CD patients, and may even be present 
prior to the onset of gastrointestinal symptoms. Abnormalities of the musculoskeletal system, such 
as sacro-ileitis, ankylosing spondylitis, peripheral arthritis are the most frequent EIMs in CD. 
Classical symptoms of UC are bloody diarrhoea, tenesmus and abdominal pain 75,76. Nocturnal 
defaecation is also frequently reported. Systemic symptoms of malaise, anorexia, or fever are 
features of a severe presentation 22. EIMs in UC include arthropathy, episcleritis and erythema 
nodosum and may accompany the presentation in about 10% of cases 20. Another important EIM in 
patients with UC is primary sclerosing cholangitis (PSC). Hence, elevated liver enzymes combined 
with GI symptoms are highly indicative of UC and PSC 22.  
As outlined in the ESPGHAN revised Porto criteria 2, diagnosing IBD in children and adolescents 
now requires a combination of clinical evaluation and endoscopic, histological, radiological, and/or 
biochemical investigations 2,34,35,76-81. Upper and lower gastrointestinal endoscopies and histological 
examination are essential to assess the extent and activity of IBD 82. 
 
1.6 Treatment 
 
In the absence of a curative treatment, the overall aim of managing childhood IBD is to reduce 
symptoms, to optimise growth, and to maintain or improve quality of life, whilst minimising toxicity 
related to drugs over both the short and long term.  
Treating active inflammation in IBD involves two phases, i.e. induction and maintenance of 
remission. Current treatments available encompass three main areas: nutrition, medical options, and 
surgery. Exclusive enteral nutrition (EEN) with polymeric formulas is used as induction treatment, 
but drugs for IBD are considered as either induction therapy or maintenance treatment, with some 
drugs being used for both. Surgery is required to either manage complications or as a last resort in 
case of treatment-resistant inflammation.  
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As reliable predictors of response to treatment are currently lacking in clinical practice, two 
therapeutic approaches (i.e. “step-up” versus “top-down”) are being used, mainly based on disease 
presentation at diagnosis. However, response to treatments still remains unpredictable, hence there 
is a need to escalate or de-escalate therapies according to the disease activity and behaviour of 
individual patients. A “step-up” therapeutic approach consists of escalating initially with 
corticosteroids, then with immunomodulators, and finally with biological therapies only if a treatment-
refractory course evolves 74,75. (Figure 1.5) An alternative “top-down” strategy (i.e. starting with a 
combination of biologics and immunosuppressants and “de-escalating” if possible) aims to achieve 
higher remission rates, restore “mucosal healing”, and decrease the rate of surgeries and 
hospitalizations in children with particularly severe disease onset by preventing mucosal and 
transmural damage to the intestinal wall 76-85.  
Nowadays, an individualised approach according to the peculiarities of each patient’s disease 
behaviour remains the best way to optimise the treatment strategies available. In fact, although early 
aggressive therapy is supported by clinical trials, it needs to be balanced with safety concerns 
regarding the indiscriminate use of potent immunosuppressants 67. Over-treating patients destined 
to develop an indolent disease course might expose them to rare but potentially life-threatening side 
effects of such drugs, including opportunistic infections 86, demyelination 87, and malignancy 88. In 
addition, indiscriminate use of biologics upfront is extremely expensive 67. 
 
 
 
Figure 1.5 Treatment strategies for paediatric IBD. 5-ASA: 5-Aminosalicylates; 6-MP: 6-mercaptopurine. 
(Taken from: Aloi M, et al. Nat Rev Gastroenterol Hepatol 2014 89) 
 
With regards to paediatric CD, the most recent NICE guidelines suggest that a course of a 
conventional gluco-corticosteroid (e.g. oral prednisolone, i.v. methylprednisolone or hydrocortisone) 
should be offered as a first line treatment to induce remission in patients with a first presentation or 
a single inflammatory exacerbation of CD in a 12-month period 27.  
STEP-UP ­   
vs 
TOP-DOWN ¯ 
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EEN with polymeric formulas represents an equally effective alternative to conventional gluco-
corticosteroids for the induction of remission in children for whom there is concern about growth or 
side effects 90,91. EEN offers the advantage of improving the patient nutritional status as well as 
enabling the mucosa to heal at much the same rate as is achievable with corticosteroids 92-96. 
5-aminosalicylates (5-ASA) are used for induction treatment of mild to moderate UC and for 
maintenance of UC at any disease severity 75, whereas the role of these medications is currently 
unsupported for children with CD 27. Mesalazine and sulfasalazine are the 5-ASAs of choice.  
 
The main drugs currently used for maintenance treatment of paediatric IBD are thiopurines (i.e. 
azathioprine or mercaptopurine), 5-ASAs and biologics. Additionally, methotrexate, cyclosporine and 
tacrolimus are alternative options when first line treatment fails.  
Thiopurines are purine analogues used for the maintenance of disease remission in patients with 
CD and UC; they include the prodrug azathioprine (AZA) and the antimetabolite 6-mercaptopurine 
(6-MP) 97,98. These drugs are steroid sparing agents and are able to block the rapid proliferation of T 
and B lymphocytes involved in inflammatory processes, which results in immunosuppression 98,99. 
Thiopurines are also used effectively to maintain surgically-induced remission in CD 99. The use of 
thiopurines is limited by an extensive spectrum of adverse events in up to almost half of patients, 
particularly within the first 12 months of treatment. Adverse effects include myelotoxicity, 
hepatotoxicity and pancreatitis 40,98,100.  
Methotrexate (MTX), a dihydrofolate reductase inhibitor, has become one of the principal alternatives 
to thiopurines as a maintenance treatment 101,102 and is a first-line treatment option in patients who 
have concomitant inflammatory arthritis. Adverse events associated with MTX include flu-like 
symptoms, nausea and vomiting, transaminitis and, less frequently, myelosuppression, which may 
require an adjustment in dosage or drug withdrawal 103.  
Biologics are a relatively new class of drugs 104-106. The most frequently used for children are 
antibodies against TNF-alpha such as infliximab (IFX) or adalimumab (ADA). While IFX is licensed 
for use in children from 6 to 17 years of age, ADA is only approved for paediatric CD and is still off-
label for paediatric UC 34,75,107.  
One-year response and remission rates for IFX in luminal disease are reported as up to 90% and 
55%-60%, respectively 108-110. Repeated administration of IFX can lead to immunogenicity in some 
patients, with possible loss of efficacy and delayed-type hypersensitivity 111,112. A low proportion of 
children with CD (10%-25%) are primary anti-TNF non-responders, i.e. they fail to respond after a 
six-weeks induction course. More commonly, however, the formation of antibodies against the drug 
over time can result in a secondary loss of response. Concomitant treatment with either thiopurines 
or MTX has been shown to hinder this process 111. In anti-TNF antibody naive children, the one-year 
remission rate for ADA is 45%, and its efficacy has been documented in nearly two-thirds of patients 
for whom IFX was unsuccessful 113. 
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Anti-TNF agents are also used as a primary induction option for children with active perianal 
fistulising disease, in combination with targeted antibiotic and surgical intervention. 
With regards to the use of biologics for maintenance of remission in children with UC, IFX (approved 
by the Food and Drug Administration for children ≥ 6 years of age with moderately-to-severely active 
UC) should be considered for treatment of cases with persistently active, or steroid-dependent UC, 
uncontrolled by 5-ASA and thiopurines. IFX should also be considered for steroid-refractory (whether 
oral or intravenous) disease 75,114.  
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1.6.1 Surgical treatment 
 
The role of surgery in the management of paediatric IBD lies in treating complications as well as 
complementing the management of cases resistant to medical treatment.  
Overall, approximately 50-80% of patients with CD will undergo surgery during the course of their 
disease 34. The most common interventions include treatment of strictures causing symptoms of 
obstruction, or other complications such as fistula formation, perforation or failure of medical therapy. 
In patients with localised ileo-caecal CD, ileo-caecal resection is frequently performed as a useful 
surgical option to treat the isolated inflammation of this area.  
For patients with severe, treatment-resistant UC, colectomy (and formation of ileostomy) is still a last 
resort 75. Resecting the colon in patients with severe UC that is non-responsive to medical options 
represents a cure, as, by definition, UC only involves the large bowel. The main down side is the 
formation of an ileostomy which generally remains unreversed until adulthood. At this stage, ileo-
anal pouch or ileal pouch-anal anastomosis are the preferred methods of choice for re-joint and 
reversal of ileostomy. Due to the major advances in the field, a laparoscopic surgical approach can 
be used safely in children with low complication rates and superior cosmetic results 75. 
 
1.7 Natural history of paediatric IBD 
 
The natural history of paediatric IBD is characteristically unpredictable, but data available so far 
shows that 25–33% of IBD patients with a non-complicated form of the disease transition to a 
stricturing or internal and perianal penetrating disease after 5 years, i.e. one third of patients, if 
undertreated, will transition from a non-complicated to a complicated disease state if followed up for 
a sufficient time 115 – 122. 
In particular, a number of studies so far suggest a more severe disease phenotype and course in 
childhood onset IBD compared to adult patients. Vernier-Massouille G et al. described the 
complicated behaviour of CD in 29% of children at diagnosis and in 59% during the follow-up 123. 
Intestinal surgery is required in as many as 80% of children with CD, with more than 10% of them 
having permanent stoma formation 115-117. Post-surgical relapses occur in 50% of children with CD 
compared to 20-30% of adult patients after 5 years, with variability depending on disease location 
124-127. 
In UC, the cumulative rate of colectomy in children is 8% at 1 year, 15% at 3 years, and 20% at 5 
years following diagnosis 128. 
Whilst patients with CD have higher mortality rates with respect to the general population, this has 
not been observed for UC patients 128-131. 
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1.8 Disease prognostic biomarkers in IBD 
 
The behaviour of IBD varies unpredictably among patients 67 and increasing evidence suggests that 
early, risk-stratified treatment (i.e. specific to those who will develop a severe disease phenotype) is 
likely to improve long-term disease outcomes 132,133. 
The development of a reliable prognostic biomarker would enable the stratification of patients based 
on their predicted risk for a poor or benign prognosis, which would lead to personalised treatment. 
Patients destined to experience an aggressive form of the disease could receive appropriately robust 
intervention from the point of diagnosis, while those who will experience a more indolent disease 
course could be treated with more conservative therapeutic approaches with a lower risk of toxicity, 
as appropriate 67,134,135. 
 
Although the biomarker concept is old, so far very few useful parameters have been identified in IBD 
136-138. Whilst a number of candidate biomarkers for IBD have been explored, ranging from genetic 
predictors (SNP-based risk scoring system) 45,115,139-141, and biochemical tests (in isolation or 
combination) 142-148, to endoscopic, histological 138,147 and clinical parameters 83,148-153, none have 
made it into routine clinical practice due to limitations in sensitivity, specificity or practical feasibility. 
 
Recent paediatric literature has shown convincing results of a correlation between PUCAI score at 
3 months over diagnosis and long-term outcomes (including risk for colectomy) in children with UC 
148-150. Although the use of this predictor is recommended in clinical practice, it is only applicable to 
UC and it is not accessible at diagnosis as it is based on response to treatment after 3 months. 
However, it might be of limited help to severe children in whom progression to severe pancolitis 
requiring colectomy could be already irreversible at that stage. 
Faecal calprotectin is an example of a helpful tool for monitoring disease activity during the follow-
up, as it enables the early prediction of relapses and prompt treatment escalation. However, it does 
not provide an overall prediction of disease severity and cannot be used to stratify patients based 
on risk at the time of diagnosis 154.  
 
In summary, the main limitations in developing prognostic biomarkers so far have included failure to 
fulfil the classic traits of an ideal biomarker test (i.e. simple, accurate, easy to perform, minimally 
invasive, cheap, rapid and reproducible), low sensitivity, specificity and/or prognostic predictive 
values, lack of validation in independent cohorts, or inconsistent results when validation has been 
attempted. As a result, we are currently not in the position to advise children and parents at the point 
of diagnosis on disease outcomes, and hence are unable to propose a tailored, potentially more 
individualised treatment strategy. There is therefore a great need for prognostic biomarkers for the 
prediction of clinical outcomes and therapeutic effects in IBD.   
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1.8.1 CD8 T-cell gene expression signatures are promising prognostic biomarkers in adult 
IBD 
 
Recent progress in the field of prognostic biomarkers in autoimmune diseases has been made by 
McKinney et al. 74 They identified a common CD8 T-cell transcriptional signature in two unrelated, 
autoimmune diseases: systemic lupus erythematosus (SLE) and ANCA-associated vasculitis (AAV). 
This signature predicted disease prognosis in both conditions 74.  
Leading on from these findings, the group tested the potential value of CD8+ T-cell gene expression 
as a prognostic biomarker in adult onset IBD. Indeed, based on analyses of a large, prospectively 
recruited patient cohort, unsupervised clustering of IBD patient-derived CD8+ T-cell gene expression 
profiles separated patients into two distinct groups. Importantly, these groups differed significantly in 
their disease outcome as evaluated by the number of treatment escalations required 67. Furthermore, 
the specific signature, i.e. set of genes that are differentially expressed between the two groups, was 
found to overlap with genes forming the prognostic signature in SLE and AAV (Figure 1.6 A-C). 
Together, these findings suggest the presence of a common CD8+ T-cell gene expression signature, 
which can be used to predict disease outcome in SLE, AAV and adult-onset IBD. 
With the aim of identifying the potential underlying biological mechanisms at play, the group went on 
to demonstrate that CD8+ T-cell exhaustion strongly correlates with a better prognosis in these 
conditions. These findings were supported by demonstrating a major overlap of the disease 
prognostic CD8+ T-cell expression signatures with an “exhaustion signature” as well as the ability of 
the latter to divide patients according to the disease outcome. In addition, a more recent publication 
by McKinney et al. focused on the process of T-cell exhaustion during chronic infection, a mechanism 
that inhibits the immune response and facilitates viral persistence 155 (Figure 1.6 D-F). 
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Figure 1.6 Summary of the main findings from studies on adult prognostic IBD signature and T-cell exhaustion 
signature (A., B. and C. are taken from Lee, J.C., et al. The Journal of Clinical Investigation 2011 67. D. E. and 
F. are taken from McKinney, E.F., et al. Nature 2015 155). A. shows CD8+ gene expression Consensus 
Clustering plots of adult CD and UC patients showing detection of subgroups IBD1 and IBD2. B. gives a Venn 
diagram illustrating the overlap between the gene signatures that distinguish the respective subgroups in CD, 
UC, and SLE/AAV. The statistical significance of each overlap was determined using a hypergeometric test. 
In C. survival analysis shows that the groups identified (IBD 1 and IBD2) have significantly different disease 
courses. In D., a heatmap shows hierarchical clustering of CD8+ T cell that are “exhausted” (blue) and “non-
exhausted” (red) in IBD patient subgroups defined from the primary division of the cluster dendrogram. In E., 
Kaplan-Meier curves show censored flare-free survival for the adult IBD cohort. In F. scatterplots show 
normalised flare-rate against duration of follow-up for IBD patient subgroups. 
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1.9 Hypothesis and aims 
 
We hypothesise that CD8+ T-cell gene expression can predict disease outcome in children that are 
newly diagnosed with IBD. Furthermore, we speculate that CD8+ T-cell DNA methylation may 
provide the epigenetic underpinning of prognostic gene expression signatures. 
 
The specific aims of our study are:  
 
- To apply the prognostic CD8+ T-cell signature and the T-cell exhaustion signature identified in adult 
patients to a cohort of children that are newly diagnosed with IBD and test their ability to 
differentiate patients based on the disease outcome; 
- To investigate the existence of paediatric-specific prognostic CD8+ T-cell expression signatures; 
- To investigate the use of CD8+ T-cell DNA methylation as an alternative prognostic biomarker, 
and/or elucidate a potential epigenetic signature that underlies variations in gene expression.  
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CHAPTER 2 
____________________________________ 
 
Materials and Methods 
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2.1 Patient cohorts 
 
This study was undertaken at Cambridge University Hospitals – NHS Foundation Trust in the 
Department of Paediatric Gastroenterology, Hepatology and Nutrition. 112 treatment-naïve, 
Caucasian patients aged between 5 and 16 were recruited prospectively at the point of IBD diagnosis 
between March 2013 and March 2016. Diagnosis was made according to current guidelines 
(ESPGHAN Porto criteria 2) and included upper and lower gastrointestinal endoscopies and 
histological examination. A sample of peripheral blood for the purification of CD8 + T lymphocytes 
was taken on the day of diagnosis, i.e. before any treatments were started. Exclusion criteria 
included any patient with gastrointestinal and/or extra-intestinal diseases other than IBD, and any 
controls. 
Patients were recruited for this project under an encompassing study (Genomics and Epigenetics in 
Paediatric Gastrointestinal and Immune Mediated Disease – GEPaedGI) which received ethics 
approval from the Central Cambridge Research Ethics Committee (REC 12/EE/0482) in November 
2012 for the prospective enrolment of paediatric patients undergoing endoscopic investigation at 
Addenbrooke’s Hospital, Cambridge, to support a clinical diagnosis. All investigations were carried 
out according to the Declaration of Helsinki and Good Clinical Practice Guidelines. 
The final number of patients (samples) analysed was established through data pre-processing 
(bioinformatic analysis). Following the removal of samples that failed quality control, 107 samples 
remained and were included in the study (67 CD and 40 UC). 
Table 2.1 illustrates the patient population demographics as well as the number of samples analysed 
at each step. Information on clinical outcomes including the number of treatment escalations, the 
use of biologics and the number of surgical interventions in the paediatric cohorts analysed is also 
included.  
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Paediatric 
population 
recruited (CD8+ 
T lymphocytes 
purified) 
Gender Diagnosis Age at 
diagnosis 
(years) 
Main clinical 
outcomes 
n (%) 
Number of patients 
removed from the 
analysis 
Initial population  
n=112 
M 71 
F 41 
CD and 
IBD-U CD-
like 71 
 
UC and 
IBD-U UC-
like 41 
Average 
12.4 ±   
SD 2.4 
 
Range 5-16 
 
 
  
Unsupervised 
analysis n=107 
 
 
 
M 67 
F 40 
CD and 
IBD-U CD-
like 67 
 
UC and 
IBD-U UC-
like 40 
Average 
12.41 ±   
SD 2.44 
 
Range 5-16 
 
0 treat escal 
25 (23%) 
1 treat escal 
34 (32%) 
2 treat escal  
20 (19%) 
3 treat escal 
20 (19%) 
4 treat escal  
8 (7%) 
Biologics 
39 (36%) 
Surgery 
6 (5.6%) 
Outliers as per QC 
report: n=4 
 
Incomplete clinical 
information as 
patient lost in follow-
up: n=1 
WGCNA analysis 
n=98 
 
 
M 60 
F 38 
CD and 
IBD-U CD-
like 60 
 
UC and 
IBD-U UC-
like 38 
Average 
12.33 ±   
SD 2.511 
 
Range 5-15 
 
0 treat escal 
23 (24%) 
1 treat escal 
32 (33%) 
2 treat escal  
18 (18%) 
3 treat escal  
18 (18%) 
4 treat escal  
7 (7%) 
Biologics 
30 (31%) 
Surgery 
3 (3%) 
Patients treated with 
biologics at time 0, 
i.e. within 8 weeks 
from diagnosis: n=9 
 
Table 2.1. Population flow-chart, demographics and summary of the main disease outcomes. CD: Crohn’s 
disease; SD: standard deviation; UC: ulcerative colitis; F: female; IBD-U: IBD unclassified; M: male; QC: quality 
control; treat escal: number of treatment escalations during follow-up; WGCNA: weighted gene co-expression 
network analysis. 
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2.2 Clinical information 
 
All patients were followed for 1.5 years in our unit as part of their routine clinical care, and extensive 
clinical data including parameters at diagnosis (e.g. presence of diarrhoea, rectal bleeding, weight 
loss, EIMs, perianal disease, disease activity scores) and information on disease course and 
outcomes (e.g. number of treatment escalations, use of biologics, number of unplanned inpatient 
days, IBD related surgical intervention) was collected by the same researcher from the hospital 
patient electronic database (EPIC).  
Appendix 1 on page 174 summarises the definitions, measurement units and normal values of each 
clinical item collected; Appendix 2 on page 165 shows the complete clinical database that was 
collected and used. 
Appendices 3 (page 200) and 4 (page 205) show the IBD activity scores at diagnosis: Paediatric 
Crohn's Disease Activity Index (PCDAI) and Paediatric Ulcerative Colitis Activity Index (PUCAI) 34-
35.  
Appendix 5 on page 207 outlines the classification of IBD by disease location according to the Paris 
classification 13. 
 
2.2.1 Severity score 
 
In order to take into account that a severe disease course is reflected in a number of individual 
disease outcome measures, a specific disease severity score was developed by considering the key 
parameters that are strong indicators of disease outcome (Figure 2.1). This summary score was 
used as an additional outcome measure to correlate with CD8+ T-cell specific molecular signatures. 
 
 
 
Figure 2.1 Severity scores for CD and UC used to provide an overall estimate of disease course severity and 
to identify predicting modules (signatures) through WGCNA analysis. IFX: Infliximab. 
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2.3 Collection of blood samples and purification of CD8 + T-cells 
 
Blood samples were obtained at diagnosis from all patients during the endoscopic procedure while 
under general anaesthetic (Table 2.2). Whole blood samples were collected in Falcon tubes with 4% 
sodium citrate. Samples were immediately sent to the lab for processing as per cell separation 
protocol 156 (Appendix 3 on page 200). 
 
Age of the 
patient 
Volume of blood 
(ml) 
Volume of 4% sodium citrate (1ml/10ml of blood) 
5-10 years 10 1 
10-16 years 25 2.5 
 
Table 2.2 Volume of blood collected according to patient age.  
 
Samples were diluted in a 1:2 ratio with MACS rinsing buffer. Peripheral blood mononuclear cells 
(PBMCs) and neutrophils were isolated by centrifugation over Ficoll (Histopaque 1077) (density 
gradient separation). Following the removal of the plasma, the PBMC interface was transferred to a 
fresh Falcon tube and after several wash and centrifugation steps, CD8+ and CD8- T lymphocytes 
were separated through anti CD8 microbeads and magnetic sorting (auto-MACS). CD8+ T 
lymphocyte samples were stored at -80°C until required for further processing. 
See Appendix 3 on page 200 for further details on the CD8+ T-cell separation protocol. 
 
2.4 Purity assessment via Fluorescence Activated Cell Sorting (FACS)  
 
Flow cytometry was performed on selected samples following CD8+ T cell isolation using BD 
Fortessa to determine the level of purity. The CD3-PE and CD8-APC antibodies were used (BD 
Pharmingen), along with the Zombie Aqua Fixable Viability Kit (Biolegend). 
A total of 8 randomly selected samples were subjected to flow cytometry analysis, and the average 
cell purity for CD8+ T-cells was 84% (Table 2.3). 
Figure 2.2 demonstrates the process of flow cytometry in one example patient sample through a 
series of plots. In A., analysis was conducted on the PBMC sample (pre-purification protocol) to 
visualise the data and set gates, with each dot on the plot representing a cell. In B. and C., the same 
gates were applied to the positive and negative fractions of T-cells, respectively. The plots were 
further gated to analyse single cells and avoid doublets and debris etc. Cells were also stained with 
Aqua Zombie to distinguish between the live and dead cells. The final image within Figures A. B. 
and C. displays the live single cells only and the gate surrounds those samples that are dual stained 
for CD3 and CD8+ T-cells.  
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For this particular sample, out of a total of 10,000 events, the CD8+ T-cell sample purity came out 
as 93.3% within the gated region of all dual stained (CD3 and CD8) live single cells, or 82.1% when 
taking into account the total cell population. The series of plots in Figure C. for the negative fraction 
(CD8-) confirms that the CD8+ T-cells have been eluted in the positive fraction, as very few appear 
in the negative plots.  
Together, this data confirms the successful isolation of CD8+ T-cells and a level of purity that was in 
the region of that reported in previous work published on adult IBD patients (Lee et al, 2011 67). 
 
Sample number % cell purity (CD8+ T-cells) 
1 75.7 
2 86.3 
3 89.3 
4 90.9 
5 93.8 
6 80.5 
7 80.7 
8 72.5 
Average cell purity 84% 
 
Table 2.3 Percentage of cell purity for CD8+ T cells across 8 samples subjected to flow cytometry. 
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A.                                                                B. 
           
C. 
 
 
 
Figure 2.2 Flow cytometry (FACS analysis) for a single patient sample. A. shows the plots for PBMC (pre-
purification protocol). B. and C. demonstrate the analysis of the positive and negative CD8 fractions 
respectively. 
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2.5 RNA and DNA Extraction 
 
DNA and RNA were extracted simultaneously from the CD8+ samples using AllPrep DNA/RNA 
MiniKit (Qiagen, UK). Quantification and purity of RNA and DNA was evaluated using a Nanodrop 
1000 spectrophotometer (Thermo Scientific, UK) and a Qubit. A ratio absorbance at 260nm/280nm 
of 1.8 for DNA was considered to be pure. 
The RNA yield was in the region of 1-4 μg and hence was sufficient for genome-wide downstream 
analysis.  
 
2.6 DNA bisulfite-conversion 
 
Prior to genome-wide DNA methylation profiling, DNA samples were bisulfite-converted using Zymo 
DNA methylation Gold kit (Zymo Research).  
DNA bisulfite-conversion consists in treating DNA with sodium bisulfite, so that unmethylated 
cytosine is converted to uracil by deamination, whereas methylated cytosine remains unchanged. 
Uracil is then amplified as thymidine. One limitation of this technic is that 5’ hydroxymethylation 
cannot be distinguished from 5’ methylation. 
The conversion reagent supplied was added to the DNA samples (500 ng). Subsequently, the 
samples were heated following 4 main steps as per manufacturer’s protocol (98^C for 10 min; 53^C 
for 30 min; 53^C for 6 min; 37^C for 30 min; steps 3 and 4 were repeated 8 times). Following, the 
samples were cooled down and stored at 4^C. Finally, the converted DNA was purified from the mix 
as per kit protocol, it was diluted in water and stored at -20^C. 
 
2.7 Microarray analysis 
Microarray analysis in this study was used to generate genome-wide transcriptional and methylation 
profiles. 
Gene expression was analysed using Affymetrix Human Gene ST 2.0 Array (Affymetrix UK Ltd, High 
Wycombe, UK), which covers 53,617 probes. 
Genome-wide DNA methylation was profiled using bisulfite-converted DNA on the EPIC BeadChip 
platforms (Illumina, Cambridge, UK). EPIC methylation array provides a quantitative measure for 
DNA methylation at > 850,000 single CpG sites across the genome. 
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2.7.1 Preparation of samples for microarray analysis 
As a first preparation step for gene expression microarray analysis, RNA samples were bioanalysed 
using Agilent 2100 Bioanalyser System. The kit contains RNA chips with an interconnected set of 
microchannels that is used for separation of nucleic acid fragments based on their size as they are 
driven through it electrophoretically. 
Next, the samples were prepared for hybridization onto Affymetrix Human Gene ST 2.0 microarrays 
by using the Ambion WT Expression Kit, according to the manufacturer’s instructions.  
In brief, first-strand and second-strand of cDNA were synthetized. Antisense cRNA was then 
produced by in-vitro transcription of the second strand cDNA template using T7RNA polymerase. 
Subsequently, the cRNA was then stabilized by purification aimed to remove the enzymes, salts, 
inorganic phosphates and unincorporated nucleotides. Sense-strand cDNA was then synthesized 
by reverse transcription of cRNA, using random primers, followed by hydrolysis using RNase H which 
degrades the cRNA template leaving single-stranded cDNA. 
Finally, the second-strand cDNA was purified to prepare for fragmentation and labeling. 
2.8 Bioinformatic analysis 
Bioinformatic analyses were performed by importing raw data into the statistical software “R”, 
followed by data analysis using BioConductor packages. 
 
Patients were initially analysed altogether (i.e. all IBD, n=107) and subsequently grouped by type of 
IBD (i.e. CD (n=67) and UC (n=40)). 
 
The following sub-sections provide information on the methods used for bioinformatic data analysis 
in this project. 
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2.8.1 Data pre-processing: normalisation, quality control and batch correction 
 
Quantile normalisation was performed using BioConductor package “affy” (“rma” function). Package 
“arrayQualityMetrics” was then applied to assess the quality of the normalised gene expression 
dataset, to identify outliers and proceed to their removal prior to subsequent data analysis. 
As the presence of a batch effect was noted, batch correction was performed through the “Combat” 
function (“sva” package). An adjustment for gender and type of diagnosis (i.e. CD vs UC) was also 
performed alongside batch correction, by adding these variables as co-variates. 
2.8.2 Gene filter  
The “genefilter” package was used to subset 50% of the probes (genes) with more variation in gene 
expression (var.cut-off: 0.5) from the microarray expression dataset.  
A selection of 20% of the probes (genes) with more variation in methylation (var.cut-off: 0.8) was 
used for the array methylation dataset. 
2.8.3 Hierarchical Clustering 
 
This methodology (BioConductor function “hclust”) was used to determine whether the data was 
organised in clusters, i.e. whether a substructure could be detected. In the context of this study, 
clusters are groups of samples with similar gene expression profiles. The main limitation of this 
method is that it doesn’t provide with a measure of the strength of the clustering (i.e. there is no p-
value associated to the clusters detected). 
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2.8.4 Consensus Clustering 
 
Consensus Clustering is a clustering method that indicates whether stable and reproducible clusters 
(i.e. groups) are present across a dataset 157. This analysis was performed through BioConductor 
package “ConsensusClusterPlus”. 
 
This method clusters fractions of the data and provides a consensus output, indicating whether 
stable/reproducible subgroups are present. K indicates the specified cluster counts, i.e. the number 
and membership of possible clusters within a dataset. 
The consensus matrix is summarized in several graphical displays that enable a user to decide upon 
a reasonable cluster number and membership (one example on Fig. 3.1, page 60). The graphics 
provided are heatmaps of the consensus matrices for the selected k (e.g. 2, 3, 4, 5, 6 etc.). The 
consensus matrices have items values range from 0 (never clustered together) to 1 (always clustered 
together) marked by white to dark blue.  
The consensus CDF plot shows the cumulative distribution functions of the consensus matrix for 
each k. This allows a user to determine at what number of clusters, k, the CDF reaches an 
approximate maximum, thus consensus and cluster confidence is at a maximum at this k (one 
example on Fig. 3.1, page 60). 
The Delta area graphic shows the relative change in area under the CDF curve comparing k and k-
1 (one example on Fig. 3.1, page 60). This plot allows a user to determine the relative increase in 
consensus and determine k at which there is no appreciable increase. 
Although superior to hierarchical clustering in detecting the best clustering option, Consensus 
Clustering also does not provide with a p-value expressing the strength of the clustering detected. 
Hence, we also resorted to the SigClust method described below in order to assess the significance 
of the clusters identified. 
2.8.5 SigClust Clustering 
This method tests the reliability of the clusters identified through the above methods, by using the 2-
means (k = 2) clustering index as a statistic. It assesses the significance of clustering by simulation 
from a single null Gaussian distribution. Null Gaussian parameters are estimated from the data 158.  
The null hypothesis of SigClust is that the data are from a single Gaussian distribution. The SigClust 
method uses a test statistic called the cluster index (CI) which is defined to be the sum of within-
class sums of squares about the mean divided by the total sum of squares about the overall mean.  
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SigClust is superior to the alternative clustering methods described above as it assesses the 
significance of a given clustering by calculating an appropriate p-value. 
2.8.6 Differential Gene Expression Analysis and Annotation 
 
Differential gene expression analysis (DGEA) was used to identify genes that were differentially 
expressed between groups of patients identified through Consensus Clustering. The Bioconductor 
package “Limma” was used. The threshold for the Bonferroni Correction was set at a p-value of 0.05. 
Annotation of differentially expressed genes was performed through packages “Annotate” and 
“hugene20sttranscriptcluster”. 
 
2.8.7 Gene Set Enrichment Analysis  
 
In our experiment, mRNA expression profiles were generated for thousands of genes from a 
collection of samples, which were then categorised into two groups, based on unsupervised 
clustering (Consensus Clustering).  
Gene Set Enrichment Analysis (GSEA) was used to detect whether significant differentially 
expressed genes between groups identified through Consensus Clustering were coordinately found 
within specific cellular pathways, which could elucidate aspects of the underlying biology.  
 
2.8.8 Weighted Gene Co-expression Network Analysis (WGCNA) 
 
This analysis investigates correlations between gene expression profiles and clinical information, 
including disease outcomes 159,160. BioConductor package “WGCNA” was used. 
Clinical information was collected as a “.csv” file, as shown in Appendix 2 on page 176.  
The general concept of WGCNA is the clustering of data points into modules to reduce the 
dimensions of the dataset. In the context of this study, modules are groups of genes with similar 
gene expression or similar methylation profile. Using modules relieves the necessity of multiple 
testing as the number of tests performed is not based on the size of the dataset, but rather on the 
number of modules and the clinical parameters.  
By using WGCNA, the data is clustered in modules that are then matched with clinical variables (as 
opposed to identifying clusters of samples/patients and comparing these groups for specific clinical 
outcomes with survival analysis).  
Significant correlations (positive or negative) between modules and clinical outcomes, allow for the 
identification of potential prognostic signatures of interest for those specific outcomes. 
  
 54 
2.8.9 Survival Analysis 
Censored Kaplan-Meier survival curves for events including treatment escalations, use of biologics 
and surgery were created using the function “survfit” from CRAN package “survival”, based on a 
tabulation of the number at risk and the number of events as recorded in our clinical database.  
The significance of any split observed in the Kaplan Meier plots was checked through the “coxph” 
function, which uses a Cox proportional hazards regression model. The function “summary.coxph” 
returns a summary of a fitted coxph model, displaying p-values based on a likelihood ratio, Wald test 
and score (logrank) test. 
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CHAPTER 3 
_________________________________ 
Testing the predictive value of an adult prognostic  
CD8+ T-cell and T-cell exhaustion signature  
on a paediatric patient cohort 
 56 
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3.1 Introduction 
 
Prognostic CD8 T-cell transcriptional signatures have been identified in adult autoimmune diseases 
including systemic lupus erythematosus (SLE), ANCA-associated vasculitis (AAV) and IBD by 
researchers from the Cambridge Department of Medicine 74. In particular, they identified a specific 
gene expression signature in CD8+ T-cells isolated from adult patients with IBD, which is able to 
cluster them in subgroups with different disease course and outcomes 67. In addition, a more recent 
publication from their research group focused on the process of T-cell exhaustion during chronic 
infection, a mechanism that associates with poor clearance of chronic viral infection, but conversely 
predicts better prognosis in multiple autoimmune diseases 155.  
In the first part of this thesis, we aimed to test whether the CD8 signature and the T-cell exhaustion 
signature identified as prognostic in previous studies on adult patients with IBD (Lee JC et al. 67 and 
McKinney E et al. 155) would also be able to distinguish paediatric IBD patients based on their disease 
severity. 
Our first goal was therefore to test the prognostic power of signatures available from previous studies 
in adult patients with IBD, on a prospective paediatric cohort, for the first time. 
 
3.2 Materials and methods 
 
Two alternative and complementary methods were used to address the question above: 
unsupervised clustering analysis and WGCNA. 
In the first instance, annotated gene lists corresponding to the adult prognostic signatures were used 
to filter out the matching probes from the paediatric dataset. BioConductor function “subset” was 
applied and subsetting was based on gene “entrezID”. This provided a submatrix of the paediatric 
data, only including probes related to the adult signatures of interest, and their expression levels 
across the paediatric cohort. 
Unsupervised clustering analysis (Consensus Clustering) allowed identification of reliable subgroups 
of patients, based on the gene expression profiles of this selection of probes across the dataset. 
Survival analysis (Kaplan-Meier) was then performed to compare the groups above for main disease 
prognostic outcomes including number of treatment escalations, treatment with biologics and 
surgical intervention. 
As a second step, WGCNA was performed to identify modules (i.e. groups of gene with similar gene 
expression levels) correlating with disease outcomes of interest.  
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The adult study 67 was published in 2011 and findings were mainly based on unsupervised clustering 
analysis and GSEA. WGCNA was not applied to the data in that study. We resorted to WGCNA in 
our paediatric study as an improved methodology compared to clustering analysis.  
In order to compare the paediatric and the adult data, we first ran WGCNA in the adult dataset to 
identify the modules corresponding to the adult prognostic signature, i.e. modules correlating to 
prognostic groups 1 (severe) and 2 (mild) based on number of treatment escalations. 
We then applied these modules to the paediatric data to test whether they would still show a 
correlation with disease outcomes in the paediatric cohort. More specifically, probes in the modules 
corresponding to disease severity in the adult population were first subset from the paediatric data. 
Subsequently, WGCNA was run for this selection of the paediatric data and correlations between 
modules and specific outcomes (number of treatment escalations, use of biologics, surgical 
intervention and severity score) were investigated. 
Children who were treated with biologics right at diagnosis (e.g. because of perianal disease) were 
removed from WGCNA; in fact, outcomes like “treatment with biologics” and “number of treatment 
escalations” would not have been comparable with the majority of children who received a strict step-
up treatment (i.e. escalation to biologics only after failing conventional immune-suppressants). 
Therefore, as shown in Table 2.1 (page 44), the number of patients included in the WGCNA analysis 
was 98 (60 CD and 38 UC). 
The same protocol was used to analyse all of the paediatric samples together (i.e. paediatric IBD 
cohort) as well as subgroups by type of IBD diagnosis (i.e. paediatric CD cohort and paediatric UC 
cohort). 
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3.3 RESULTS 
3.3.1 Testing the adult CD8 prognostic signature on paediatric IBD: unsupervised analysis 
In the first instance, we tested whether the adult prognostic signature identified in the study by Lee 
JC at al. 67 could also be applied to the paediatric data and whether it would identify groups of children 
with different disease course and severity. 
First, we filtered out of the paediatric data the probes corresponding to the adult prognostic signature, 
and ran Consensus Clustering analysis. Clusters based on gene expression profiles of this selection 
of the paediatric data (i.e. adult prognostic signature applied to the paediatric IBD cohort (n=107)) 
were identified as shown in Figure 3.1.  
At this stage, we focused on whether the groups identified through Consensus Clustering (Figure 
3.1C k5: group 1 (n=95) vs groups 2+3+4+5 (n=12), renamed as group 2) would differ in respect to 
their disease course and outcomes. 
Survival analysis did not identify a significant split between the groups in terms of treatment 
escalations, use of biologics and surgical intervention during a follow-up of 1.5 years (Kaplan Meier 
curves on Figure 3.2). 
In summary, applying the adult signature to the paediatric data did not generate any significant split 
in clinical outcomes.  
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Figure 3.1 Consensus Clustering plots of a selection of the paediatric data (paediatric IBD cohort, n=107) 
based on the CD8 prognostic signature identified in adult IBD 67. In A. Consensus Cumulative Distribution 
Function (CDF) shows at what number of clusters (k) consensus and cluster confidence reach a maximum. In 
B. Delta area plot shows the relative change in area under the CDF curve, i.e. at which k there is no further 
appreciable increase. K5 is identified as the strongest clustering split. In C. clusters are shown as dendrogram 
(top), colour bar, and gene expression heatmap. 
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A.                                                                         B. 
 
C.                                                                                   D. 
   
E.                                                                                   F. 
    
 
Figure 3.2. Kaplan Meier curves for the paediatric IBD cohort (n=107) comparing group 1 (n=95) and group 2 
(n=12) identified through Consensus Clustering limited to genes in the adult CD8 prognostic signature (Lee 
JC et al. 67) (Figure 3.1C). Patients in the two groups are compared for the following outcomes: A) first 
treatment escalation; B) second treatment escalation; C) third treatment escalation; D) fourth treatment 
escalation; E) use of biologics; F) surgical intervention. 
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3.3.2 Testing the adult CD8 prognostic signature on paediatric IBD: WGCNA 
 
In order to address whether the adult CD8 prognostic signature would identify groups of children with 
different disease outcome, we first ran WGCNA on the adult data 67 and identified modules that 
correlated strongly with disease severity in the adult cohort, i.e. adult group IBD1 (severe) vs adult 
group IBD2 (mild) based on number of treatment escalations (More details on this step are provided 
in the Materials and Methods part on page 53). 
Module-trait relationships from WGCNA analysis of the adult data is shown in Figure 3.3, where a 
selection of modules strongly correlated with the clinical variable “Group” (i.e. adult prognostic 
groups IBD1 (severe) vs IBD2 (mild)) is highlighted. 
At this stage, the top modules identified above were applied to the paediatric data. Probes included 
in these modules were filtered out of the paediatric dataset and modules were matched against 
clinical outcomes including use of biologics, surgical intervention, number of relapses, number of 
unplanned inpatient days and severity score. 
As shown in Figure 3.4 (top positively correlated modules in the adult dataset), and in Figure 3.5 (top 
negatively correlated modules in the adult dataset), there was no significant correlation (i.e. 
correlation index < 0.3) between modules and clinical outcomes in the paediatric dataset. 
Together, these results suggest that the prognostic CD8+ T-cell gene expression signatures derived 
from an adult cohort of IBD patients are unable to differentiate children suffering from IBD at the 
point of diagnosis when applied to their CD8+ T-cells. 
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Figure 3.3 WGCNA. Module-trait relationships in the adult dataset (Lee JC et al. 67) (n=67) showing modules 
(colour bars on the y axis) and clinical variables (x axis) including “Group” (i.e. different prognostic groups IBD1 
(severe) vs IBD2 (mild) based on number of treatment escalations during the follow-up). The figures in the plot 
refer to correlation index and p-value (in brackets). A selection of the modules highlighted correlates 
significantly with “Group” either directly (in red) or inversely (in blue). 
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Figure 3.4 WGCNA. Module-trait relationships in the paediatric dataset (paediatric IBD cohort, n=98). 
Significant prognostic signatures from the adult study 67 (i.e. top modules directly correlated to the outcome 
“number of treatment escalations”) were applied to the paediatric dataset and plotted against clinical outcomes. 
The plot shows modules (colour bars on the y axis) and clinical variables (x axis) including number of relapses, 
use of biologics, surgical intervention and severity score. The figures in the plot refer to correlation index and 
p-value (in brackets).  
 
Figure 3.5 WGCNA. Module-trait relationships in the paediatric dataset (paediatric IBD cohort, n=98). 
Significant prognostic signatures from the adult study  67 (i.e. top modules inversely correlated with the outcome 
“number of treatment escalations”) were applied to the paediatric dataset and plotted against clinical outcomes. 
The plot shows modules (colour bars on the y axis) and clinical variables (x axis) including number of relapses, 
use of biologics, surgical intervention and severity score. The figures in the plot refer to correlation index and 
p-value (in brackets).  
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3.3.3 Testing the T-cell exhaustion signature on the paediatric IBD cohort 
 
We investigated whether the T-cell exhaustion signature, identified in adults as predictive towards a 
severe course of autoimmune diseases (including IBD) 155, would also play a role in paediatric IBD 
and whether it may serve as a prognostic biomarker. 
Genes (probes) related to the T-cell exhaustion signature were filtered out from the paediatric IBD 
dataset (n=107) in order to look for presence of clusters based on the gene expression profiles in 
this selection (Figure 3.6). The heatmap on figure 3.6 identifies two groups of patients (dendrogram 
on top), although no clear difference was detected in their gene expression profiles. 
We performed survival analysis to test whether the groups identified by applying the T-cell 
exhaustion signature to the paediatric data (Figure 3.6) would differ in respect to their disease course 
and outcomes (Kaplan Meier curves shown in Figure 3.7). The survival analysis did not identify any 
significant split between these groups with regard to treatment escalations, use of biologics and 
surgical intervention (Figure 3.7). 
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Figure 3.6 Heatmap showing gene expression profiles of the paediatric IBD cohort (n=107) for a selection of 
probes included in the T-cell exhaustion signature identified in adult autoimmune diseases 155. On the y axis, 
the exhaustion signature is represented as a dendrogram (left) and it is colour coded for up-regulated and 
down-regulated exhaustion genes as a list. On the x axes the paediatric patients (paediatric IBD cohort, n=107) 
are shown as a dendrogram tree (top). Colour bars on the top of the chart display gender and type of diagnosis 
(i.e. CD vs UC) for each patient, as well as the unsupervised Consensus Clustering groups. 
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A)                                                                    B)             
                
C)                                                                               D) 
                    
E)                                                                                 F)       
                
 
Figure 3.7 Kaplan Meier curves for the paediatric IBD cohort (n=107) comparing group 1 (n=80) and group 2 
(n=27) identified in Figure 3.6. Patients in the two groups are compared for the following outcomes: A) first 
treatment escalation; B) second treatment escalation; C) third treatment escalation; D) fourth treatment 
escalation; E) use of biologics; F) surgical intervention. 
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At this stage, we moved on to split our paediatric cohort (n=107) by type of diagnosis, in order to 
analyse CD (n=67) and UC (n=40) separately, in consideration of the fact that clinical outcomes and 
indications to treatments including use of biologics and surgical intervention may differ according to 
the specific type of IBD. Nevertheless, separate analyses of CD and UC paediatric cohorts produced 
similar findings. No split in disease outcomes including number of treatment escalations, use of 
biologics and surgery was observed by applying the adult CD8 prognostic signature 67 or the T-cell 
exhaustion signature 155. (Figure 3.8). 
 
 
 
 
Figure 3.8 Heatmaps showing gene expression profiles of the paediatric CD (n=67) and UC (n=40) cohorts 
for a selection of probes included in the T-cell exhaustion signature identified in adult autoimmune diseases 
155. On the y axis, the exhaustion signature is represented as a dendrogram (left) and it is colour coded for up-
regulated and down-regulated exhaustion genes as a list. On the x axes the paediatric patients are shown as 
a dendrogram tree (top). Colour bars on the top of the chart display gender and type of diagnosis for each 
patient, as well as the unsupervised Consensus Clustering groups. 
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3.3.4 Distinct differences in disease behaviour of children diagnosed with IBD compared to 
adults. 
In light of our findings so far, we speculated whether the inability of an adult derived expression 
signature to predict disease outcome in children could be related to differences in phenotype 
between adult and paediatric onset IBD. We therefore compared the two cohorts based on 
overlapping clinical outcome parameters that were available for both patient groups (i.e. number of 
treatment escalations). 
Indeed, as shown in Figure 3.9 (and reported in Table 2.1, on page 44), in the paediatric cohort the 
number of treatment escalations was significantly higher than in the adult population, suggesting that 
children suffer an overall worse disease outcome and hence could display a “severe” CD8+ 
expression signature. 
 
 
 
Figure 3.9 Comparison of clinical outcome “number of treatment escalations” between the paediatric cohort 
(box plot on the right) and the adult data available from the study by Lee JC et al. 67; Ad_IBD1: Adult poor 
prognosis group (n=25), Ad_IBD2: Adult good prognosis group (n=42); Paed_IBD: Paediatric cohort altogether 
(n=107). 
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3.4 Discussion 
 
In this chapter, we show that the adult CD8 and T-cell exhaustion signatures identified as predictive 
for disease severity in adult IBD patients do not generate a similar split when applied to our paediatric 
IBD cohort. 
The use of two complementary approaches (i.e. unsupervised analysis and WGCNA) showing no 
significant differences in outcome between the groups identified, and no correlation between 
modules and specific outcomes respectively, negates any prognostic power of these adult signatures 
in our paediatric cohort.  
The analysis was conducted on the joint paediatric IBD cohort as well as on the paediatric CD and 
UC cohorts separately, within an attempt of removing any confounders related to different indications 
to treatments and disease outcomes in the two types of IBD. Nevertheless, results were consistently 
negative across the three datasets analysed. This may suggest that in paediatric onset IBD, T-cells 
are not exhausted, therefore paediatric patients are predisposed to a more severe disease 
phenotype and course compared to adults, as they would lack of the protective role of T-cell 
exhaustion.  
This would also explain the absence of a significant split in clinical outcomes between the groups 
identified, as all of the children would fall into the “severe prognosis group”. 
The comparison between children and adults in terms of number of treatment escalations during the 
follow-up shown in Figure 3.9 would also stand in support of this hypothesis. 
At this stage, in the absence of a prognostic role of adult CD8 and T-cell exhaustion signatures in 
our paediatric cohorts, we went on to address the question of whether “paediatric specific” CD8 
signatures further able to differentiate patients according to disease outcome exist. 
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CHAPTER 4 
____________________________________ 
Identification of paediatric CD8+ T-cell expression derived 
prognostic signatures 
 72 
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4.1 Introduction 
As demonstrated in previous chapters, applying a prognostic T-cell expression signature derived 
from an adult IBD patient cohort to our paediatric data, did not yield any significant separation of 
patients according to disease outcome. Furthermore, T-cell exhaustion did not seem to differ in CD8+ 
T-cells derived from paediatric IBD patients, leading us to speculate whether a paediatric specific 
disease prognostic expression profile could be identified. 
Hence, we next went on to identify such a signature by analysing the paediatric cohort in isolation 
using the same analyses as previously described (i.e. unsupervised clustering methods and 
WGCNA). 
 
4.2 Materials and methods 
 
Samples were first analysed altogether (paediatric IBD cohort, n=107), and then split by type of IBD 
diagnosis (CD (n=67) and UC (n=40)). 
Normalisation, removal of outliers and batch correction were performed in the joint IBD dataset 
(n=107). Samples were then split by type of IBD diagnosis (i.e. CD and UC).  
 
4.2.1 Unsupervised clustering analysis 
 
Unsupervised clustering analysis included Hierarchical Clustering and Consensus Clustering. 
Hierarchical Clustering (BioConductor function “hclust”) was used to test whether datasets had a 
substructure, i.e. whether clusters and subclusters could be identified, based on the patients’ gene 
expression profiles. 
Consensus Clustering was utilised as a more accurate clustering methodology to identify presence 
of stable groups across the dataset, and to choose the strongest clustering option. Top clustering 
option is shown by the Consensus Distribution Function (CDF) plot; it consists in the recommended 
number of clusters amongst various output options displayed and indicated with letter “k” followed 
by progressive numbering. Prior to running Consensus Clustering, the data was filtered by using the 
R package “genefilter” and half of the genes (var. cutoff: 0.5) with more variation in gene expression 
across this dataset were selected. The strength of clusters across the data was also tested by using 
R package “SigClust”, a method that measures the reliability of clusters by using the 2-means (k = 
2) clustering index as a statistic (Figure 4.1). 
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Figure 4.1 SigClust analysis of CD8+ T-cell gene expression data from the paediatric IBD cohort (n=107). In 
A., SigClust analysis assesses the significance of clustering by simulation from a single null Gaussian 
distribution. The null hypothesis of SigClust is that the data is from a single Gaussian distribution. In B., the 
SigClust method uses a test statistic called the cluster index (CI) which is defined to be the within-class sums 
of squares about the mean divided by the total sum of squares about the overall mean. 
 
When significant differences in disease outcomes were observed between groups identified through 
Consensus Clustering, GSEA was also performed to compare the groups identified and to detect 
whether they would differ in molecular pathways of biological relevance. 
 
4.2.2 WGCNA 
 
WGCNA was performed on 98 IBD patients (i.e. 60 CD and 38 UC) due to the removal of those 
treated with biologics from the time of diagnosis. In fact, in terms of disease course and clinical 
outcomes these patients would not be comparable with the remainder of the children receiving a 
strict step-up treatment approach. 
As a first step, WGCNA aligns the gene expression data with clinical information collected on a “.csv” 
spreadsheet (Figure 4.2; the “.csv” file used is shown in table format in Appendix 2, on page 176). 
The next step of WGCNA consists in the choice of a soft thresholding power 159,160 based on the 
criterion of scale-free topology (Figure 4.3).  
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This number represents the stage where the network (based on gene expression similarity in this 
context) stabilises, and corresponds to the point where the curves for scale independence and mean 
connectivity reach a plateau. 
At this stage, it is possible to compute and display the number of modules identified in each dataset. 
We set up minimal module size at 20 probes/module. An example plot of module detection in the 
joint IBD cohort (n=98), based on clustering dendrogram of genes and on their dissimilarity according 
to topological overlap, is shown in Figure 4.4. Moreover, Table 4.1 shows the corresponding list of 
modules identified and their size.  
Final step of WGCNA is testing the correlation between modules and measured clinical traits. The 
summary profile (eigengene) for each module is used for correlation with clinical variables imported 
from the “.csv” file (and aligned with the data in the initial step of WGCNA). Correlation index and p-
value are provided for each match between modules and clinical variables, which in this context 
allowed the identification of modules (signatures) more significantly correlated with disease 
outcomes. 
In order to test further the prognostic role of the relevant modules (signatures) identified, probes in 
these modules of interest were subset from the paediatric dataset. Consensus Clustering was then 
run on this selection and the patient groups identified were compared for the specific outcomes 
through survival analysis. In case of a significant split, GSEA was also performed to detect whether 
the groups identified would differ in molecular pathways of biological relevance. 
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Figure 4.2 WGCNA analysis of the paediatric IBD cohort (n=98). Sample dendrogram and trait heatmap.  
The dendrogram on top displays the samples in this cohort based on hierarchical clustering of their CD8 gene 
expression data. The heatmap below aligns all clinical information available for each patient / sample 
presented as colour coded for each variable. For dichotomous variables (e.g. presence of symptoms): white = 
no, red = yes; for continuous variables (e.g. blood test results): white = minimum, red = maximum, shades of 
red for values in between. 
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Figure 4.3 WGCNA. Analysis of network topology in the paediatric IBD cohort (n=98) for various soft-
thresholding powers. The left panel shows the scale-free topology index (y axis) as a function of the soft-
thresholding power (x axis). The right panel displays the mean connectivity (degree, y axis) as a function of 
the soft-thresholding power (x axis). Soft thresholding power chosen: 12. 
 
 
 
Figure 4.4 Clustering dendrogram of genes, with dissimilarity based on topological overlap, together with 
assigned module colours (paediatric IBD cohort, n=98). 
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Module Number Genes in each 
module 
Module Number Genes in each 
module 
0  24396 12 71 
1 837 13 71 
2 664 14 52 
3 588 15 47 
4 583 16 44 
5 502 17 41 
6 411 18 34 
7 249 19 34 
8 175 20 30 
9 169 21 30 
10 118 22 29 
11 96 23 27 
 
Table 4.1 WGCNA of the paediatric IBD cohort (n=98). Module numbers and their size. The label 0 is reserved 
for genes outside of all modules, so it is not a module per se. 
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4.3 RESULTS  
 
4.3.1 Analysis of CD8+ T-cell gene expression profiles from the combined paediatric IBD 
cohort 
 
In the first instance, we performed unsupervised clustering analyses on the combined paediatric IBD 
cohort (i.e. samples from children with CD and UC). 
We started with Hierarchical Clustering to investigate whether the CD8+ gene expression data in 
this cohort had a substructure, i.e. whether clusters of samples with similar gene expression levels 
could be detected. As shown in Figure 4.5 A, the data clustered into two main groups, with an 
approximate size of 2/3 and 1/3 respectively. Each group was clustered into further subgroups. 
We then performed Consensus Clustering as an alternative clustering methodology to identify 
presence of reliable stable clusters within the dataset. The consensus output identified three more 
solid groups of patients across this dataset. Figure 4.5 D shows the Consensus Clustering plot for 
k=3, which provides the strongest clustering: the three groups differ in size, with a larger group 
including approximately 90% of the patients and two smaller groups accounting in total for 10% of 
the patients. 
As a further step, we addressed the question of whether the groups identified through Consensus 
Clustering (Figure 4.5 D: group 1 (n=99) vs groups 2+3 (n=8), renamed as group 2) would differ in 
respect to their disease course and outcomes, i.e. whether groups identified in this cohort based on 
the paediatric CD8 gene expression profiles would be different in their disease outcomes. 
Survival analysis did not identify significant differences between these groups in terms of use of 
biologics, treatment escalations and surgical intervention (Kaplan Meier curves on Figure 4.6). 
Although children in group 2 were milder in their disease course, the difference in the groups’ size 
affected the power of the survival analysis which didn’t reach significance except for the outcome 
“first treatment escalation” (Figure 4.6 A). 
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Figure 4.5. In A. Hierarchical Clustering of the CD8 gene expression data in the paediatric IBD cohort (n=107). 
In B. CDF: Consensus Cumulative Distribution Function showing at what number of clusters, k, consensus 
and cluster confidence reach a maximum. In C. Delta area plot showing the relative change in area under the 
CDF curve, with no further appreciable increase at k=3. k3 is identified as the strongest clustering option. In 
D. Consensus Clustering plot (for k=3) of gene expression data from the paediatric IBD cohort (n=107): clusters 
are shown as dendrogram (top), colour bar, and gene expression heatmap. 
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A.                                                                         B. 
     
  C.                                                                          D. 
         
E.                                                                           F.        
   
 
Figure 4.6 Kaplan Meier curves for the paediatric IBD cohort (n=107) comparing group 1 (n=99) and group 2 
(n=8) identified through Consensus Clustering (Figure 4.5 D). Patients in the two groups are compared for the 
following outcomes: A) first treatment escalation; B) second treatment escalation; C) third treatment escalation; 
D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
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Next, in order to address the same question, i.e. whether a paediatric CD8 signature to be able to 
predict disease severity exists, we also performed WGCNA of CD8+ T-cell gene expression profiles 
from the combined paediatric IBD cohort. More specifically, WGCNA aimed to explore whether the 
gene expression data would be organised in groups of genes with similar expression (modules) and 
whether any of these modules would correlate with specific disease outcomes reflecting severity of 
disease course. The ultimate aim of WGCNA was to detect specific signatures for clinical variables 
reflecting disease severity (i.e. outcomes). 
 
First, as shown in Table 4.1 on page 78, 22 modules were detected in this cohort.  
As a next step, correlations between modules and measured clinical traits were tested. Figure 4.7 
displays correlations between each module and all clinical variables recorded, while in Figure 4.8 
only the modules of relevance to disease outcomes are shown.  
As recapped in Table 4.2., module lightyellow [5] and module pink [11] showed the strongest 
correlation with disease outcomes, though correlation indexes only ranged between ± 0.18 and ± 
0.24. Module light yellow was correlated with several clinical outcomes, i.e. number of relapses, 
number of treatment escalations and use of biologics.  
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Figure 4.7 WGCNA. Module-trait associations. Paediatric IBD cohort (n=98). Each row corresponds to a 
module eigengene, column to a trait. Each cell contains the corresponding correlation index and p-value 
(colour-coded, numbers not displayed in this plot, but available separately). The table is colour-coded by 
correlation according to the colour legend (i.e. 1 = highest direct correlation, red; -1 = highest inverse 
correlation, blue). Red frames highlight modules that correlate with outcomes more than they do with clinical 
parameters at diagnosis. The green frame highlights clinical outcome measures (e.g. number of treatment 
escalations, surgery, use of biologics etc.) 
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Figure 4.8 WGCNA. Module-trait associations. Paediatric IBD cohort (n=98). Selection of modules correlated 
with clinical outcomes from Figure 4.7. On the x axis are variables related to the disease at diagnosis (e.g. 
gender, abdominal pain at diagnosis, diarrhoea and disease activity score at diagnosis (e.g. PCDAI, PUCAI)) 
followed by variables describing disease outcomes (e.g. use of biologics, surgery). On the y axis, selected 
modules are listed (indicated by colour names). The plot shows how these modules correlate more strongly 
(directly or inversely) with disease outcomes than they do with parameters describing disease at diagnosis. 
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CLINICAL OUTCOMES CORRELATION INDEX P-VALUE 
BIOLOGICS 
ME lightyellow [5] 0.24 0.02 
TREATMENT ESCALATIONS 
ME lightyellow [5] 0.18 0.07 
6 MONTHS STEROID FREE REMISSION 
ME lightyellow [5] - 0.24 0.02 
ME blue [13] - 0.21 0.03 
ME yellow [14] - 0.24 0.02 
ME midnightblue [16] 0.2 0.05 
RELAPSES 
ME lightyellow [5] 0.18 0.07 
SURGERY 
ME pink [11] - 0.22 0.03 
 
Table 4.2 WGCNA. Paediatric IBD cohort (n=98). Main modules correlating with disease outcomes. 
 
Finally, in order to test the prognostic power of the modules (signatures) identified, we subset their 
corresponding probes from this dataset (i.e. paediatric IBD cohort, n=98) and performed Consensus 
Clustering of this selection. We then compared the groups identified for the specific outcomes 
correlated with those modules. 
We first tested module light yellow (34 probes), correlated with number of relapses, treatment 
escalations and use of biologics. Groups based on this module were identified through Consensus 
Clustering, as shown in Figure 4.9 C (k3: group 1 (n=67) vs groups 2+3 (n=31), renamed as group 
2). The survival analysis performed to compare these groups for clinical outcomes (Figure 4.10) did 
not show significant differences. 
We then tested module pink (175 probes), correlated with surgical intervention. Groups identified 
through Consensus Clustering (Figure 4.11 C k3: group 1 (n=85) vs groups 2+3 (n=13), renamed as 
group 2) did not show a significant split on the Kaplan Meier analysis for surgical intervention. 
Nevertheless, whilst none of the patients in group 2 had surgery, 3 patients in group 1 required 
surgical intervention.  
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Figure 4.9 Consensus Clustering of a selection of probes included in the WGCNA module light yellow (34 
probes), correlated with “number of relapses”, “number of treatment escalations” and “use of biologics”. In A. 
CDF: Consensus Cumulative Distribution Function showing at what number of clusters, k, the consensus and 
cluster confidence reach a maximum. In B. Delta area plot showing the relative change in area under the CDF 
curve, with no further appreciable increase at k=3. k3 is identified as the strongest clustering option. In C. 
Consensus Clustering plot for k=3.  
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A)                                                                     B) 
              
C)                                                                             D) 
            
E)                                                                             F 
                 
 
Figure 4.10 Kaplan Meier curves comparing the groups identified in 4.9 C (group 1: n=67 and group 2 (i.e. 
2+3): n=31) for the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third 
treatment escalation; D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
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Figure 4.11 Consensus Clustering of a selection of probes included in the WGCNA module pink (175 probes), 
correlated to “surgical intervention”. In A. Consensus Cumulative Distribution Function (CDF) showing at what 
number of clusters, k, the consensus and cluster confidence reach a maximum. In B. Delta area plot showing 
the relative change in area under the CDF curve, with no further appreciable increase at k=3. k3 is identified 
as the strongest clustering option. In C. Consensus Clustering plot for k=3.  
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Figure 4.12 Kaplan Meier curves comparing the groups identified in 4.11 C (group1: n=85 and group2 (i.e. 
2+3): n=13) for the event “surgical intervention”. 
 
In summary, in the joint paediatric IBD cohort we could not identify strong correlations between gene 
expression profiles (i.e. signatures, modules) and prognostic outcomes, neither by using 
unsupervised clustering analyses nor by applying WGCNA.  
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4.3.2 Analysis of CD8+ T-cell gene expression profiles from the paediatric CD cohort 
 
In this section, we applied the same methods utilised above (i.e. unsupervised clustering analyses 
and WGCNA) to analyse our paediatric CD cohort separately (n=67) and identify whether signatures 
specific to paediatric CD able to differentiate children for their disease severity exist. 
First, we performed Hierarchical Clustering to investigate whether the CD8+ gene expression data 
in this cohort had a substructure. Similarly to what identified in the combined IBD cohort, this dataset 
also clustered into two main groups, with an approximate size of 3/4 and 1/4 respectively (Figure 
4.13 A). Each group was clustered into further subgroups. 
Consensus Clustering analysis identified three more solid groups of patients throughout the dataset. 
Figure 4.13 C shows the top Consensus Clustering plot, where k=3 provides the strongest clustering: 
one bigger and two smaller clusters were identified, with an approximate size of 3/4 and 1/4 for group 
1 and for groups 2+3, respectively. 
Next, we tested whether the groups identified through Consensus Clustering (Figure 4.13 D k3: 
group 1 (n=54) vs groups 2+3 (n=13), renamed as group 2) would split for disease outcomes, i.e. 
whether groups identified in this cohort based on CD8 gene expression profiles would differ in terms 
of disease severity over time. Survival analysis identified a significant difference between the groups 
in respect to treatment with biologics, as well as differences (though not reaching significance) in 
number of treatment escalations (Kaplan Meier curves on Figure 4.14). In particular, group 2 
included milder patients who never had a fourth treatment escalation and only one child in this group 
was treated with biologics, as opposed to 60% of the children in group 1.  
As previously shown for the paediatric IBD dataset, the difference in size between group 1 and 2 
affected the power of the survival analysis performed (Figure 4.14). 
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Figure 4.13. In A. Hierarchical Clustering of the CD8 gene expression data in the paediatric CD cohort (n=67). 
In B. CDF: Consensus Cumulative Distribution Function showing at what number of clusters, k, the consensus 
and cluster confidence reach a maximum. In C. Delta area plot showing the relative change in area under the 
CDF curve, with no further appreciable increase at k=3. k3 is identified as the strongest clustering option. In 
D. Consensus Clustering plot (for k=3) of the gene expression data from the paediatric CD cohort (n=67). 
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A) B) 
                    
C)                                                                        D) 
                 
E)                                                                          F)                         
 
Figure 4.14 Kaplan Meier curves for the paediatric CD cohort (n=67) comparing group 1 (n=54) and group 2 
(n=13) identified through Consensus Clustering (Figure 4.13 D). Patients in the two groups are compared for 
the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third treatment 
escalation; D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
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We went on to perform differential gene expression analysis (DGEA) in order to investigate 
significant differentially expressed genes between the groups of patients identified through 
Consensus Clustering (k3). As summarised in Figure 4.15, 12461 differentially expressed genes 
were identified in this cohort between Consensus Clustering group 1 (n=54) and group 2 (n=13); 
6342 of these were annotatable.  
We also performed GSEA to detect whether genes differentially expressed between groups 1 and 2 
identified through Consensus Clustering were organized in molecular pathways of biological 
relevance. 
 
4562 gene sets had positive enrichment score (i.e. they correlated with group 1); 68 were 
significantly enriched at nominal p-value < 1% and 397 were significantly enriched at nominal p-
value < 5%. None of them was significant at FDR < 25%. Genes in the core enrichment included IL6 
receptor, IL12 receptor, IL18 receptor, IFN induced proteins, chemokine receptor 2, chemokine 
ligands, TNF-alpha induced proteins, toll-like receptors. 
310 gene sets had negative enrichment score (i.e. they correlated with group 2); of these, only 2 
were significantly enriched at nominal p-value < 5%, and none at nominal p-value < 1%. None was 
significant at FDR < 25%. Genes in the core enrichment included IL15 receptor, IL22 receptor, IL25, 
TNF ligands, IFN alpha and chemokine ligands. 
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Figure 4.15 Main GSEA findings from the paediatric CD cohort (n=67). Groups as identified through Consensus 
Clustering. In A. Heatmap of the top 50 features for each phenotype (Consensus Clustering groups 1 vs 2). In 
B. Plot showing correlation between the ranked genes and the groups 1 and 2. In C. Butterfly plot showing the 
top 100 positive and negative correlations between gene rank and the ranking metric score (i.e. first and last 
100 genes in the ranked list). Observed correlation and permuted (1%, 5%, 50%) positive and negative 
correlations are shown for the top genes. This plot describes the extent to which dataset permutations change 
the correlation between gene rank and the ranking metric score. 
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At this stage, in order to address the same question, i.e. whether a paediatric CD8 signature able to 
predict disease severity in this cohort exists, we also performed WGCNA. WGCNA was run on 60 
paediatric CD samples, as patients with perianal disease who were treated with biologics from the 
time of diagnosis were removed from this step.  
 
The 27 modules identified in this cohort were tested for correlations with measured clinical traits, as 
shown in Figure 4.16. In Figure 4.17 only the modules of relevance to disease outcomes are shown.  
As recapped in Table 4.3, the positive and negative correlation indexes for the top modules ranged 
between +0.25 and +0.33, and between –0.28 and -0.37, respectively. Module orange was correlated 
with several clinical outcomes, including number of relapses, number of treatment escalations and 
severity score.  
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Figure 4.16 WGCNA. Paediatric CD cohort (n=60). Module-trait associations. Each row corresponds to a 
module eigengene, column to a trait. Each cell contains the corresponding correlation index and p-value 
(colour-coded, numbers not displayed on this plot). The table is colour-coded by correlation according to the 
colour legend (i.e. 1 = highest direct correlation, -1 = highest inverse correlation). Red frames highlight modules 
that correlate with outcomes more than they do with clinical parameters at diagnosis. The green frame 
highlights clinical outcome measures (i.e. number of treatment escalations, surgery, use of biologics, severity 
score). 
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Figure 4.17 Selection of modules correlated with clinical outcomes from Figure 4.16. On the x axis are variables 
related to the disease at diagnosis (i.e. gender, abdominal pain at diagnosis, diarrhoea and disease activity 
score at diagnosis (i.e. PCDAI)) followed by variables describing disease outcomes (including use of biologics, 
surgery, steroid resistance, severity score). On the y axis, selected modules are listed (indicated by numbers 
and colour names). The plot shows how these modules correlate more strongly (directly or inversely) with 
disease outcomes than they do with parameters describing disease at diagnosis. 
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CLINICAL OUTCOMES CORRELATION INDEX P-VALUE 
BIOLOGICS 
ME orange [14] 0.29 0.03 
ME cyan [24] 0.33 0.01 
TREATMENT ESCALATIONS 
ME orange [14] 0.3 0.02 
6 MONTHS STEROID FREE REMISSION 
ME orange [14] - 0.37 0.004 
RELAPSES 
ME orange [14] 0.33 0.009 
INPATIENT DAYS 
ME darkturquoise [28] 0.25 0.05 
SEVERITY SCORE 
ME orange [14] 0.29 0.02 
ME darkgrey [20] -0.28 0.03 
 
Table 4.3 WGCNA. Paediatric CD cohort (n=60). Main modules correlating with disease outcomes. 
 
In order to test the prognostic role of these modules further, we filtered out of this dataset the probes 
corresponding to modules of interest for specific outcomes. We then performed Consensus 
Clustering of this selection to test whether the groups of patients identified would differ in respect to 
those outcomes. 
 
First, we tested module orange (29 probes), correlated to number of relapses, treatment escalations 
and severity score. Groups based on this module were identified through Consensus Clustering, as 
shown in Figure 4.18 C (k3: group 1 (n=52) vs groups 2+3 (n=8), renamed as group 2). The survival 
analysis performed to compare these groups for clinical outcomes (Figure 4.19) showed significant 
differences in first and second treatment escalations. Children in group 2 were overall milder than 
group 1, with only one patient in group 2 receiving biologics as opposed to 60% of those in group 1.  
 
We then tested modules orange and cyan (111 probes), correlated to treatment with biologics. 
Groups identified through Consensus Clustering (Figure 4.20 C k2: group 1 (n=44) vs groups 2 
(n=16)) did not differ significantly in respect to use of biologics (Kaplan Meier curve in Figure 4.21).  
 
Finally, we looked at the signature in module dark turquoise (34 probes) correlated to the clinical 
outcome “unplanned inpatient days”. As shown in Figure 4.23, survival analysis of the groups 
identified through Consensus Clustering (Figure 4.22 C, k3: group 1 (n=36) vs groups 2+3 (n=24), 
renamed as group 2) showed significant splits between the groups for number of treatment 
escalations and use of biologics. 
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Figure 4.18 Consensus Clustering of a selection of probes included in the WGCNA module orange (29 probes), 
correlated to “number of relapses”, “number of treatment escalations” and “severity score”. In A. CDF: 
Consensus Cumulative Distribution Function, showing at what number of clusters, k, the consensus and cluster 
confidence reach a maximum. In B. Delta area plot, showing the relative change in area under the CDF curve, 
with no further increase appreciable at k=3. k3 is identified as the strongest clustering option. In C. Consensus 
Clustering plot for k=3.  
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A)                                                                          B) 
                     
C)                                                                          D)  
                         
E)                                                                           F) 
                           
 
Figure 4.19 Kaplan Meier curves comparing the groups identified in 4.18 C (group 1: n=52 vs group 2 (i.e. 
2+3): n=8) for the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third 
treatment escalation; D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
 
 
 102 
 
 
 
Figure 4.20 Consensus Clustering of a selection of probes included in the WGCNA modules orange and cyan 
(111 probes), correlated to “use of biologics”. In A. CDF: Consensus Cumulative Distribution Function, showing 
at what number of clusters, k, the consensus and cluster confidence reach a maximum. In B. Delta area plot, 
showing the relative change in area under the CDF curve, with no further appreciable increase at k=2. k2 is 
identified as the strongest clustering option. In C. Consensus Clustering plot for k=3.  
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Figure 4.21 Kaplan Meier curves comparing the groups identified in 4.20 C (group 1: n=44 vs groups 2: n=16) 
for the outcome “use of biologics”. 
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Figure 4.22 Consensus Clustering of a selection of probes included in the WGCNA module dark turquoise (34 
probes), correlated to “unplanned inpatient days”. In A. CDF: Consensus Cumulative Distribution Function, 
showing at what number of clusters, k, the consensus and cluster confidence reach a maximum. In B. Delta 
area plot showing the relative change in area under the CDF curve, with no further appreciable increase at 
k=3. k3 is identified as the strongest clustering option. In C. Consensus Clustering plot for k3.  
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A)                                                                       B) 
                              
C)                                                                              D) 
                     
E)                                                                               F) 
              
 
Figure 4.23 Kaplan Meier curves comparing the groups identified in 4.22 C (group 1: n=36 vs group 2 (i.e. 
2+3): n=24) for the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third 
treatment escalation; D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
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Given the significant differences in outcomes identified between the Consensus Clustering groups 
related to module dark turquoise, we also performed GSEA in order to detect whether such groups 
would differ in molecular pathways of biological relevance. 
 
As summarised in Figure 4.24, 2647 gene sets had positive enrichment score (i.e. they showed 
enrichment at the top of the ranked list and correlated with group 1); 6 of these were significantly 
enriched at nominal p-value < 1% and 23 were significantly enriched at nominal p-value < 5%. None 
of them was significant at FDR < 25%. 
Genes in core enrichment included NKT recognition sequences, GABA receptors, chemokine 
ligands, TNF receptors, TNF receptor associated factors, TNF and IFN induced proteins, IL15 and 
toll-like receptor 3.  
2225 gene sets had negative enrichment score (i.e. they showed enrichment at the bottom of the 
ranked list and correlated with group 2); of these, 8 were significantly enriched at nominal p-value < 
1% and 42 were significantly enriched at nominal p-value < 5%. None was significant at FDR < 25%. 
Genes in core enrichment included TNF receptors, IFN alpha, chemokine receptors, GABA 
receptors, VIP receptor 1. 
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Figure 4.24 Main GSEA findings from the paediatric CD cohort (n=60). Groups as identified through Consensus 
Clustering (module dark turquoise correlated to “number of unplanned inpatient days”). In A. Heatmap of the 
top 50 features for each phenotype (Consensus Clustering groups 1 vs 2). In B. Plot showing correlation 
between the ranked genes and the groups 1 and 2. In C. Butterfly plot showing the top 100 positive and 
negative correlation between gene rank and the ranking metric score (i.e. first and last 100 genes in the ranked 
list). Observed correlation and permuted (1%, 5%, 50%) positive and negative correlations are shown for the 
top genes. This plot describes the extent to which dataset permutations change the correlation between gene 
rank and the ranking metric score. 
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In summary, the paediatric signatures identified from WGCNA of the paediatric CD cohort (i.e. 
module orange correlated with “number of relapses”, “number of treatment escalations” and “severity 
score”, and module dark turquoise correlated with “number of unplanned inpatient days”) did identify 
groups of children with significant differences in disease outcomes (Kaplan Meier curves from the 
survival analysis), although with correlation indexes within a range of only 0.25-0.37.  
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4.3.3 Analysis of CD8+ T-cell gene expression profiles from the paediatric UC cohort 
 
In this section, we briefly summarise the main results obtained by applying the same analyses shown 
above (i.e. unsupervised clustering analyses and WGCNA) to our cohort of children with UC (n=40). 
First, we performed Hierarchical Clustering which demonstrated the presence of a substructure, with 
two groups including 1/3 and 2/3 of the patients approximately (Figure 4.25 A). 
Consensus Clustering of this dataset identified five more solid groups of patients throughout the 
gene expression data as shown in Figure 4.25 B and C, where k=5 provides the strongest clustering. 
As previously observed in the paediatric CD cohort, the clusters of patients identified in this dataset 
also differ in size, with one group including 90% of patients, and the remaining 10% of them clustering 
out. 
As a next step, we tested whether the groups identified through Consensus Clustering (Figure 4.25 
D, k5: group 2 (n=35, renamed as group 1) vs groups 1+3+4+5 (n=5, renamed as group 2)) would 
differ in respect to their disease course and outcomes, i.e. whether groups identified in this cohort 
based on their CD8 gene expression profiles would have different disease severity over time. 
Survival analysis identified differences, although not reaching significance, between these two 
groups in respect to number of treatment escalations, use of biologics and surgical intervention 
(Kaplan Meier curves on Figure 4.26). In particular, group 2 in the survival analysis (i.e. Consensus 
Clustering groups 1,3,4,5 combined) included milder patients who never had more than two 
treatment escalations, and who were never treated with biologics, as opposed to 20% of the children 
in group 1. Also, children in group 2 never had surgical intervention as opposed to 2 children in group 
1 who required colectomy.  
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Figure 4.25. In A. Hierarchical Clustering of the CD8 gene expression data in the paediatric UC cohort (n=40). 
In B. CDF: Consensus Cumulative Distribution Function showing at what number of clusters, k, the consensus 
and cluster confidence reach a maximum. In C. Delta area plot showing the relative change in area under the 
CDF curve, with no further appreciable increase at k=5. k5 is identified as the strongest clustering option. In 
D. Consensus Clustering plot (for k=5) of gene expression data from the paediatric UC cohort (n=40). 
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A) B) 
                               
C)                                                                   D) 
                    
E)                                                                   F) 
                         
             
Figure 4.26 Kaplan Meier curves for the paediatric UC cohort (n=40) comparing group 1 (n=35) and group 2 
(n=5) identified through Consensus Clustering (Figure 4.25 D). Patients in the two groups are compared for 
the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third treatment 
escalation; D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
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At this stage, we went on to perform differential gene expression analysis (DGEA) using R package 
“limma” in order to investigate significantly differentially expressed genes between the groups of 
patients identified through Consensus Clustering (k5). In this cohort, 3549 differentially expressed 
genes were identified between Consensus Clustering group 1 (n=35) and group 2 (n=5); 1312 of 
these were annotatable. We also performed GSEA to detect whether genes differentially expressed 
between groups 1 and 2 identified through Consensus Clustering were organised into molecular 
pathways of biological relevance. As summarised in Figure 4.27, 4290 gene sets had positive 
enrichment score (i.e. they showed enrichment at the top of the ranked list and correlated with group 
1); 111 of these were significantly enriched at nominal p-value < 1% and 603 were significantly 
enriched at nominal p-value < 5%. 1165 were significant at FDR < 25%. Genes in core enrichment 
included chemokine ligands, VIP receptor 1, IL2, IL22 receptor, IL25 and GABA receptor. 
582 gene sets had negative enrichment score (i.e. they showed enrichment at the bottom of the 
ranked list and correlated with group 2); of these, only 1 was significantly enriched at nominal p-
value < 1% and 6 were significantly enriched at nominal p-value < 5%. None was significant at FDR 
< 25%. Genes in core enrichment included IL1 receptor associated proteins, integrins, IL18 receptor, 
bromodomains and IL11 receptors. 
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Figure 4.27 Main GSEA findings from the paediatric UC cohort (n=40). Groups as identified through Consensus 
Clustering. In A. Heatmap of the top 50 features for each phenotype (Consensus Clustering groups 1 vs 2).  
In B. Plot showing correlation between the ranked genes and groups 1 and 2. In C. Butterfly plot showing the 
top 100 positive and negative correlations between gene rank and the ranking metric score (i.e. first and last 
100 genes in the ranked list). Observed correlations and permuted (1%, 5%, 50%) positive and negative 
correlations are shown for the top genes. This plot describes the extent to which dataset permutations change 
the correlation between gene rank and the ranking metric score. 
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As a next step, we performed WGCNA as an alternative and complementary method to investigate 
the existence of paediatric specific prognostic signatures in our UC cohort. WGCNA was performed 
on 38 patients as 2 of them with acute severe onset who needed biologic treatments from the time 
of diagnosis were excluded from this analysis.  
Forty modules were identified in this dataset. Their correlation with the clinical data collected is 
shown on Figure 4.28 while Figure 4.29 shows an excerpt from Figure 4.28 where only the modules 
of relevance to disease outcomes are shown.  
As shown in Table 4.4, modules yellowgreen [18] and steelblue [36] correlate with multiple outcomes, 
i.e. treatment with biologics, number of relapses, surgical intervention (colectomy) and severity 
score. 
Moreover, modules yellowgreen and steelblue showed high inverse correlation (< -0.5) with clinical 
outcome “surgical intervention”. Overall, positive and negative correlation indexes ranged between 
+0.31 and +0.38, and between -0.29 and -0.59, respectively. 
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Figure 4.28 WGCNA. Paediatric UC cohort (n=38). Module-trait associations. Each row corresponds to a 
module eigengene, column to a trait. Each cell contains the corresponding correlation and p-value (colour-
coded, numbers not displayed on this plot). The table is colour-coded by correlation according to the colour 
legend (i.e. 1 = highest direct correlation, -1 = highest inverse correlation). Red frames highlight modules that 
correlate with outcomes more than they do with clinical parameters at diagnosis. The green frame highlights 
clinical outcome measures (i.e. number of treatment escalations, surgery, use of biologics etc.) 
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Figure 4.29 WGCNA. Paediatric UC cohort (n=38). Excerpt from Fig. 4.28 displaying modules correlated with 
clinical outcomes. On the x axis are variables related to the disease at diagnosis (i.e. gender, abdominal pain 
at diagnosis, diarrhoea and disease activity score at diagnosis (i.e. PUCAI)) followed by variables describing 
disease outcomes (use of biologics, surgery, steroid resistance, severity score etc.). On the y axis, selected 
modules are listed (indicated by colour names). The plot shows how these modules correlate more strongly 
(directly or inversely) with disease outcomes than they do with parameters describing disease at diagnosis. 
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CLINICAL OUTCOMES CORRELATION INDEX P-VALUE 
BIOLOGICS 
ME yellowgreen [18] -0.36 0.03 
ME steelblue [36] -0.4 0.01 
RELAPSES 
ME yellowgreen [18] -0.31 0.06 
6 MONTHS STEROID FREE REMISSION 
ME darkgreen [8] 0.34 0.04 
INPATIENT DAYS 
ME darkgreen [8] -0.35 0.03 
ME steelblue [36] -0.39 0.01 
SEVERITY SCORE 
ME skyblue [6] 0.31 0.06 
ME yellowgreen [18] -0.29 0.08 
ME steelblue [36] -0.29 0.08 
SURGERY 
ME darkgreen [8] -0.36 0.03 
ME orangered4 [16] 0.38 0.02 
ME sienna3 [17] 0.35 0.03 
ME yellowgreen [18] -0.51 9e-04 
ME orange [26] -0.32 0.05 
ME grey60 [32] -0.4 0.01 
ME steelblue [36] -0.59 9e-05 
ME lightyellow [39] -0.44 0.005 
 
Table 4.4 WGCNA. Paediatric UC cohort (n=38). Main modules correlating with disease outcomes.  
 
Next, as previously shown in the joint paediatric IBD cohort and in the paediatric CD cohort, we 
tested the modules identified in this dataset to correlate with disease outcome parameters by 
subsetting them and by running Consensus Clustering of this selection. Subsequently, we performed 
survival analysis to compare the groups of patients identified for specific outcomes. 
In summary, the signature for “number of unplanned inpatient days” (modules darkgreen and steel 
blue, 104 probes in total) generated Consensus Clustering groups (Figure 4.30 C) with non-
significant differences in disease outcomes, although children in group 2 had fewer treatment 
escalations and surgical interventions (Kaplan Meier curves in Figure 4.31).  
The signature for “use of biologics” (modules yellowgreen and steelblue, 75 probes in total) also 
generated a non-significant split (Figure 4.32 C shows the Consensus Clustering plots while in Figure 
4.33 the Kaplan Meier curve is displayed). 
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Distinctively, the signature for “surgical intervention” (modules darkgreen, yellowgreen, orange, 
grey60, steelblue, lightyellow, 345 probes in total), did generate a significant split in outcome 
between the groups identified, as shown in Figure 4.34 C (Consensus Clustering plots) and in Figure 
4.35 (Kaplan Meier curve).  
For this specific signature, in view of the significant difference in outcome identified, we also 
performed GSEA to detect whether these groups would differ in molecular pathways of biological 
relevance. 
As summarised in Figure 4.36, 1700 gene sets had positive enrichment score (i.e. they showed 
enrichment at the top of the ranked list and correlated with group 1); only 1 of these was significantly 
enriched at nominal p-value < 1% and 24 were significantly enriched at nominal p-value < 5%. None 
was significant at FDR < 25%. Genes in the core enrichment included IL23 receptor, chemokine 
receptors, IL1 receptor, IL2 receptor, IL11 receptor, IL12 receptor, IL32, GABA receptor and TNF 
receptor. 
3172 gene sets had negative enrichment score (i.e. they showed enrichment at the bottom of the 
ranked list and correlated with group 2); of these, 58 were significantly enriched at nominal p-value 
< 1% and 158 were significantly enriched at nominal p-value < 5%. None was significant at FDR < 
25%. Genes in the core enrichment included IL6 signal transducer, IL6 receptor and integrins. 
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Figure 4.30. Consensus Clustering of a selection of probes included in the WGCNA modules darkgreen and 
steelblue (104 probes), correlated with “unplanned inpatient days”. In A. CDF: Consensus Cumulative 
Distribution Function, showing at what number of clusters, k, the consensus and cluster confidence reach a 
maximum. In B. Delta area plot showing the relative change in area under the CDF curve, with no appreciable 
further increase at k=3. k3 is identified as the strongest clustering option. In C. Consensus Clustering plot for 
k3: groups 1+3 (n=8, renamed as group 1) vs group 2 (n=30).  
 120 
A)    B) 
                                    
C)                                                                                    D) 
                                      
E)                                                                                      F) 
                              
 
Figure 4.31. Kaplan Meier curves comparing the groups identified in 4.30 C (group 1: n=36 vs group 2 (i.e. 
2+3): n=24) for the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third 
treatment escalation; D) fourth treatment escalation; E) use of biologics; F) surgical intervention. 
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Figure 4.32 Consensus Clustering of a selection of probes included in the WGCNA modules yellowgreen and 
steelblue (75 probes), correlated with “use of biologics”. In A. CDF: Consensus Cumulative Distribution 
Function, showing at what number of clusters, k, the consensus and cluster confidence reach a maximum. In 
B. Delta area plot, showing the relative change in area under the CDF curve, with no further appreciable 
increase at k=3. k3 is identified as the strongest clustering option. k4 was chosen as second-best clustering 
option, as by choosing k3 only one patient would cluster away from the remainder. In C. Consensus Clustering 
plot for k4: group 3 (n=8, renamed as group 1) vs groups 1,2 and 4 (n=30, renamed as group 2).  
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Figure 4.33 Kaplan Meier curves comparing the groups identified in 4.32 C (group 1: n=8 vs group 2 (i.e. 
1+2+4): n=30) for the clinical outcome “use of biologics”.  
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Figure 4.34 Consensus Clustering of a selection of probes included in the WGCNA modules correlated with 
the clinical variable “surgical intervention” (345 probes). In A. CDF: Consensus Cumulative Distribution 
Function, showing at what number of cluster, k, the consensus and cluster confidence reach a maximum. In 
B. Delta area plot, showing the relative change in the area under the CDF curve, with no further increase at 
k=3. K3 is identified as the strongest clustering option. K4 was chosen as second-best clustering option 
because k3 would only separate 1 patient out of the remainder.  In C. Consensus Clustering plot for k4: group 
1 (n=22) vs groups 2+3+4 (n=16, renamed as group 2). 
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Figure 4.35. Kaplan Meier curves comparing the groups identified in 4.34 C (group 1: n=22 vs group 2 (i.e. 
2+3+4): n=16) for the outcome “surgical intervention”. 
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Figure 4.36. GSEA of the paediatric UC cohort (n=38). Groups are based on Consensus Clustering analysis 
of the selection of genes in WGCNA modules correlated to “surgical intervention”. In A. Heatmap of the top 50 
features for each phenotype (Consensus Clustering groups 1 vs 2). In B. Plot showing correlation between the 
ranked genes and groups 1 and 2. In C. Butterfly plot showing the top 100 positive and negative correlations 
between gene rank and the ranking metric score (i.e. first and last 100 genes in the ranked list). Observed 
correlations and permuted (1%, 5%, 50%) positive and negative correlations are shown for the top genes. This 
plot describes the extent to which dataset permutations change the correlation between gene rank and the 
ranking metric score. 
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In summary, whilst in this cohort we did not validate any reliable prognostic power of the signatures 
identified in adult patients 67, the paediatric signatures that emerged from WGCNA (i.e. modules 
correlated to the event “surgical intervention”) did generate groups with significantly different 
outcomes. Moreover, WGCNA correlation indices of < -0.5 suggest significant strength in the 
predictive power of these specific signatures. 
 
4.4 Discussion 
 
This chapter aimed to investigate the existence of CD8 “paediatric specific” prognostic signatures, 
in light of the fact that the adult CD8 prognostic signature and T-cell exhaustion signature did not 
generate any significant split in outcome in our paediatric cohort, as shown in chapter 3. 
In order to identify paediatric specific prognostic signatures, we resorted to the two alternative and 
complementary methods (i.e. unsupervised clustering analyses and WGCNA) used in the previous 
chapter. 
When analysing CD and UC jointly, neither method showed any significant split in outcomes between 
the groups of patients identified. Clustering analyses produced a very uneven split between patient 
groups (90%: 10%), which limited the statistical power of the survival analysis (Kaplan Meier curves) 
as the milder group only included a limited number of patients (< 10) compared with the remainder 
clustering together and showing a more severe disease course. 
WGCNA of the joint cohort only identified two modules of interest for specific outcomes, both with 
low correlation indices (< 0.25, > -0.25). In order to further test the prognostic potential of these 
modules, the corresponding probes were subset from the IBD cohort dataset and Consensus 
Clustering was performed to identify groups. These groups were then compared for specific 
outcomes through survival analysis, which failed to show a significant split. This questioned even 
further the strength of the modules identified. However, it should be pointed out that when testing 
the module correlated with “surgical intervention” in the joint cohort, the absence of a significant split 
was likely due to the limited number of events across the cohort. Although all three patients who 
underwent IBD related surgery did fall in the same Consensus Clustering group, the split in the 
survival analysis failed to reach significance. 
We considered whether the lack of strong correlations could, at least partly, be explained by the fact 
that CD and UC patients were analysed jointly, given that the two types of IBD are significantly 
different in terms of indications to specific treatments and in outcome measures, so a separate 
analysis should be preferred. We therefore went on to investigate the existence of paediatric specific 
prognostic signatures, in the CD and UC cohorts separately. 
Neater results were obtained when looking for CD8 prognostic signatures in the CD and in the UC 
datasets, with a significant split in some specific outcomes, using both unsupervised clustering (e.g. 
use of biologics in the paediatric CD cohort) and when applying WGCNA (e.g. surgical intervention 
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in the paediatric UC cohort). Groups with different outcomes identified by applying WGCNA modules 
of interest were also compared with GSEA. Top gene sets identified corresponded to those obtained 
from GSEA of the joint cohort. However, GSEA performed in the split cohort did not always reach 
FDR < 0.25. 
Overall, this part of the analysis failed to identify strong CD8 paediatric specific signatures, although 
potential modules (signatures) were identified for specific outcomes in the CD and UC cohorts. We 
speculate that the limitation in the strength of such signatures is likely due to the majority of children 
developing a severe disease phenotype, with only an extreme minority of patients presenting with 
mild indolent disease. This hypothesis would be in consistent with the findings discussed in Chapter 
3. 
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CHAPTER 5 
____________________________________ 
Testing CD8 DNA methylation profiles as potential 
prognostic biomarkers in paediatric CD 
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5.1 Introduction 
 
DNA methylation is one of the main epigenetic marks that are known to play a key role in regulating 
gene expression and cellular function in all mammals 55,56. Its role in regulating cellular function 161 
combined with high stability makes DNA methylation signatures an attractive read out for the 
development of clinical biomarkers 162-165. 
In this part of the project we aimed to test the use of genome wide CD8+ T-cell DNA methylation 
profiles as disease prognostic biomarkers in paediatric IBD.  
 
5.2 Materials and methods 
 
DNA extracted from CD8+ T-cells of 66 children with CD, who were all part of the CD cohort analysed 
for gene expression (n=67, see section 4.3.2 on page 91), was processed through Epic methylation 
array. WGCNA was performed to test whether changes in DNA methylation in CD8+ T-cells can be 
used for outcome prediction.  
BioConductor packages used were DMRcate, Minfi, 
IlluminaHumanMethylationEPICanno.ilm10b2.hg19, IlluminaHumanMethylationEPICmanifest and 
WGCNA. 
Given that methylation data is gender related, the first step of the analysis consisted in checking the 
dataset for gender prediction using the “getSex” function. As shown in Figure 5.1 A, gender was 
predicted correctly in this dataset so no further adjustment was required. All samples passed quality 
control (BioConductor function: getQC) (Figure 5.1 B). 
As our dataset was based on one tissue (i.e. blood samples only), the data was normalised by using 
quantile normalisation (preprocessQuantile function). Removal of SNPs at either the CpG 
interrogation sites or at the single nucleotide extension was then performed using the functions 
“dropLociWithSNPs” and “rmSNPandCH’. Data distribution post normalisation is displayed as M and 
beta values in Figure 5.2. 
At this stage, batch correction (ComBat function) and chromosome removal were performed (Figure 
5.3). 
As a next step prior to performing WGCNA, we filtered out of the total probes (i.e. > 100,000, 
corresponding to CpGs) the 20% that were most differently methylayed by using the function 
“genefilter”, as explained above (paragraph 2.8.2 on page 51). 
At this stage, we went on to perform WGCNA on this methylation dataset. Methods related to 
WGCNA correspond to what summarised in Chapter 4.2.2 on page 74, other than modules being 
groups of CpG with similar methylation density. Another expected difference in WGCNA of the 
methylation data compared to gene expression is a gender related effect, despite chromosome 
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removal. In particular, the presence of a strong correlation between one (or more) module(s) and the 
variable “gender” is expected. 
Set-up parameters were a soft thresholding power of 18 and minimum module size of 20. 
Number and size of the modules identified through WGCNA of 66 children with CD are shown in 
Table 5.1. 
Finally, WGCNA was also performed in a selection of this dataset, where probes corresponding to 
gene expression signatures of interest identified in the same cohort (Chapter 4.3.2 on page 91) were 
subset. 
 
  
 
Figure 5.1 In A. Gender prediction of the paediatric methylation data (n=66). MDS plot by gender, on a 
logarithmic scale. F: female; M: male; x axis and y axis represent X and Y chromosomes. In B. Quality 
control of CD8 T-cell methylation samples from 66 children with CD. 
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A)                                                                B) 
                        
C)                                                                         D) 
             
                        
Figure 5.2 CD8+ T-cell methylation data distribution plots. Beta values in A. and B. M values in C. and D. A. 
and C. are density plots. B. and D. are density bean plots.  
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A)                                                                  B) 
 
                                                        
C) 
 
 
Figure 5.3 CD8+ T-cell methylation data. MDS plots before (A.) and after (B.) batch correction. MDS plot after 
chromosome removal (C.). 
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Module Number Genes in each 
modules 
0  16648 
1 34043 
2 7362 
3 6974 
4 6250 
5 3020 
6 284 
7 69 
8 49 
 
Table 5.1 WGCNA of methylation data from the paediatric CD cohort (n=66). Module numbers and their size. 
The label 0 is reserved for genes outside of all modules, so it is not a module per se. 
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5.3 RESULTS 
 
5.3.1 WGCNA of CD8+ T-cell methylation data from 66 children with CD 
 
First, hierarchical clustering of this dataset was performed to investigate the data distribution and its 
substructure in groups and subgroups. We noted a relevant split in two main data groups of equal 
size, which was driven by differences in gender (Fig. 5.4). We then went on with WGCNA to identify 
7 modules, which were tested for their correlation with the measured clinical traits. 
As shown in Fig. 5.5 (showing correlations between modules and all clinical variables recorded for 
this patient cohort) and in Fig. 5.6 (an excerpt from Figure 5.5 where only outcome parameters are 
shown), there was no significant correlation between modules and disease outcomes. Of note, one 
module (module pink in this dataset) correlated with gender (Figure 5. 5), as expected in methylation 
datasets. 
 
 
 
 
 
 
Figure 5.4. Hierarchical clustering of the methylation data in 66 children with CD. Two main clusters and their 
subgroups are shown. 
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Figure 5.5 WGCNA. Methylation data from 66 children with CD. Module-trait associations. Each row 
corresponds to a module eigengene, column to a trait. Each cell contains correlation index and p-value (colour-
coded, numbers not displayed on this plot). The table is colour-coded by correlation according to the colour 
legend (i.e. 1 = highest direct correlation, -1 = highest inverse correlation).  
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Figure 5.6 WGCNA. Methylation data from 66 children with CD. Excerpt from Figure 5.5 showing the top 
modules for clinical outcomes. On the x axis are variables related to disease outcomes. On the y axis are 
selected modules (indicated by colour bars). Each cell contains a correlation index and a p-value (in brackets). 
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5.3.2 Analysis of a subset of the CD8 methylation data from 66 children with CD: probes 
correlated with outcomes in the gene expression dataset from the same cohort. 
 
Given the absence of significant correlations from the analysis above, we next resorted to a more 
supervised approach by subsetting from the methylation dataset those probes corresponding to 
modules that were significantly correlated with outcomes in the gene expression dataset (from the 
same patient cohort). This selection included 388,270 probes (across 66 samples). The top 20% of 
these probes that were most differentially methylated across this cohort were then selected, to obtain 
a final subset of 77,654 probes / 66 samples. 
Fifteen modules were identified and their correlation with measured clinical variables is shown in 
Figure 5.7 while Figure 5. 8 shows an excerpt from Figure 5.7 where only the modules of relevance 
to disease outcomes are shown. Correlations for use of biologics (module cyan), surgical intervention 
(modules salmon and midnightblue) and severity score (modules cyan and midnightblue) were 
identified, though correlation indexes only ranged between + 0.24 and + 0. 26 for positive 
correlations, and between – 0.28 and -0.3 for negative correlations. 
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Figure 5.7 WGCNA. Module-trait associations. CD8 methylation data from 66 children with CD: probe selection 
corresponds to top gene expression WGCNA modules from the same cohort. Each row shows a module 
eigengene, columns correspond to clinical traits. Each cell contains a correlation index and a p-value (colour-
coded, numbers not displayed on this plot). The table is colour-coded by correlation according to the colour 
legend (i.e. 1 = highest direct correlation, -1 = highest inverse correlation).  
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Figure 5.8 WGCNA. Module-trait associations. Selection of modules correlated with clinical outcomes from 
Figure 5.7. On the x axis are variables related to the disease at diagnosis (i.e. gender, age at diagnosis, 
abdominal pain at diagnosis, diarrhoea and disease activity score at diagnosis (i.e. PCDAI)) followed by 
variables describing disease outcomes (use of biologics, surgery, steroid resistance etc.). On the y axis are 
modules of interest (indicated by numbers and colour names). The plot shows how these modules correlate 
more strongly (directly or inversely) with disease outcomes than they do with parameters describing disease 
at diagnosis. 
 
At this stage, in order to test further the prognostic power of the modules identified above, the probes 
corresponding to each module of interest were subset from this dataset and Consensus Clustering 
of this selection was performed. Subsequently, survival analysis was performed to compare the 
groups identified for the specific outcomes of interest. 
First, we tested module cyan (21 CpG) correlated to the clinical variables “use of biologics” and 
“severity score”. Groups identified through Consensus Clustering are shown in Fig. 5.9. Survival 
analysis showed no significant differences between children in group 1 and 2, in respect to number 
of treatment escalations, use of biologics and surgical intervention (Fig. 5.10). 
 144 
 
 
                                                       
Figure 5.9. Consensus Clustering of a selection of probes included in the WGCNA module cyan (21 CpG) 
correlated with the clinical variables “use of biologics” and “severity score”. In A. CDF: Consensus Cumulative 
Distribution Function, showing at what number of clusters, k, the consensus and cluster confidence reach a 
maximum. In B. Delta area plot, showing the relative change in the area under the CDF curve, with no further 
appreciable increase at k=3. k3 is identified as the strongest clustering option. In C. Consensus Clustering plot 
for k3: group 1: n=45 vs groups 2 (i.e. 2+3): n=21. 
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A)                                                               B) 
                  
C)                                                                       D) 
                   
E)                                                                                            
              
 
Figure 5.10 Kaplan Meier curves comparing the groups identified in 5.9 C (group 1: n=45 vs groups 2 (i.e. 
2+3): n=21) for the following outcomes: A) first treatment escalation; B) second treatment escalation; C) third 
treatment escalation; D) use of biologics; E) surgical intervention.  
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We then performed a similar analysis subsetting probes from WGCNA modules salmon and 
midnightblue, correlated with surgery. Survival analysis failed to identify significant splits between 
the groups identified through Consensus Clustering. 
 
As a last step, we analysed male and female patients separately, aiming to correct for gender effect. 
Nevertheless, this did not increase the correlation indexes of the modules identified. 
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5.4 Discussion 
 
Testing DNA methylation profiles in CD8+ T-cells from our cohort was relevant to this project in view 
of existing evidence on the role of methylation in regulating gene expression 56 and on changes in 
methylation described in diseases including IBD 59-65. 
We aimed to explore the potential of CD8+ specific DNA methylation profiles in predicting outcome 
for children with IBD as an alternative parameter endowed with higher stability compared to gene 
expression 66, 161-164. The presence of relevant correlations with outcome would also have allowed 
us to investigate whether different DNA methylation profiles underpin specific changes in gene 
expression relevant to outcome prediction.  
The data analysis shown in this chapter failed to identify significant correlations with disease 
outcome in our paediatric cohort. Nevertheless, the analysis is still at a preliminary stage and a 
number of possible limitations must be taken into account when interpreting these results. First, the 
patient population tested only included 66 children with CD, both males and females. Data 
breakdown by gender limited the population size even further. Second, so far, we have only applied 
WGCNA to our methylation data by adjusting the protocol used for gene expression to this specific 
dataset. The different nature of the methylation dataset may not fit the WGCNA approach 
extrapolated from the gene expression protocol. There are further analyses that should be 
undertaken, in particular, supervised differential methylation analysis between groups of children 
with different disease outcome. Moreover, although WGCNA has been applied to methylation 
datasets in previous studies 65,165, the use of other computational tools to test for possible correlation 
between genome wide methylation data and disease outcome should be investigated. 
Current plans are to expand our cohort and sample size, adding more patients, including those with 
UC, and to refine and complete data analysis as discussed above on this larger cohort. Furthermore, 
as a similar project is being undertaken by our colleague adult gastroenterologists, a combined 
analysis of CD8+ methylation data from paediatric and adult patients will be available.  
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CHAPTER 6 
____________________________________ 
 
Discussion 
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6.1 Summary and conclusion 
 
The hunt for prognostic biomarkers is one of the most challenging and exciting topics in the study of 
paediatric and adult autoimmune diseases (including IBD) at present. 
Huge progress has been achieved in areas such as oncology, where bench-work has generated 
reliable genetic and histological predictors that have changed the way in which patients are treated 
by personalising their care, but a similar approach is still a “work in progress” in complex immune-
mediated conditions such as IBD 166. 
IBD is a chronic condition for which no cure has yet been developed, so there is no doubt that the 
discovery of a reliable prognostic biomarker would improve the care of children affected by the 
disease. However, whether such a discovery would really improve patients’ lives is determined by 
treatment availability. The treatments that are currently available target the immune system on 
different levels, and aim to achieve remission of the inflammatory status. However, particularly for 
patients of paediatric age, clinical and endoscopic remission is generally temporary, as children tend 
to relapse and therefore require accelerated treatment escalation 23,26,124,128. The majority of children 
with IBD have shown suboptimal response to treatment, while also being exposed to potentially 
severe side effects such as infections and malignancy 86-88,111,167. 
Increasing evidence suggests that the early, stratified treatment of patients in high-risk groups (i.e. 
those patients with the severe disease phenotype) is likely to improve the long-term disease outcome 
132. A reliable prognostic biomarker would enable us to advise children and their parents about the 
likely disease outcome at the point of diagnosis, and hence to propose a tailored, potentially more 
individualised treatment strategy and/or patient monitoring scheme. Importantly, treatment 
stratification according to likely disease outcome would avoid the unnecessary exposure of “mild” 
disease cases to potentially harmful treatment, while still providing sufficiently effective treatment to 
patients in high-risk groups.   
However, treatment availability is currently limited, particularly for paediatric IBD. As shown in Fig. 
1.5 on page 33 89, only a few drugs and/or treatment options (i.e. EEN/steroids, thiopurines, biologics 
and surgery) are available while dealing with lack or loss of response to treatments.  
The use of a “step-up approach” as opposed to a “top down strategy” has been debated for the past 
two decades. Current data show that, even in countries where a step-up approach is favoured in 
order to save the more powerful treatment options for a later stage, the majority of children will 
eventually end up needing second line immunosuppressants and nearly half of them will end up on 
biologic treatments in the long run. Based on the number of children failing to respond to treatment, 
it is becoming more and more questionable whether we are indeed able to modify the natural history 
of IBD 125,127. 
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It is therefore clear that the search for prognostic biomarkers has to proceed alongside the 
development of new drugs in order to have enough options available once patients have been 
stratified for risk at the point of diagnosis. 
One of the most promising predictors reported to date has come from work by the group of Prof. Ken 
Smith (Cambridge Department of Medicine). This group has identified a specific gene expression 
signature in CD8+ T-cells isolated from peripheral blood that correlates with disease outcome in 
adult patients with autoimmune diseases (i.e. systemic lupus erythematosus (SLE) and ANCA 
associate vasculitis (AAV)) as well as adult IBD 67. E. McKinney from the same group also identified 
a T-cell related exhaustion signature that is protective towards the development of a severe disease 
course in adult patients with auto-immune conditions, including IBD 155. 
In 2014, we set out to test, for the first time, the use of CD8+ T-cell gene expression profiles as 
disease prognostic biomarkers in children diagnosed with IBD. Our data from 107 prospectively 
recruited children did not prove a predictive role of CD8 adult signatures, which may suggest that 
there are intrinsic differences between children and adults. Moreover, unsupervised clustering 
analysis of the paediatric data consistently showed a major difference in size between groups of 
patients identified in our paediatric cohort: when the outcomes for such groups were compared, the 
fraction of patients in the mild group was approximately 10%, whereas the severe prognostic group 
made up 80–90% of the sample. This uneven split limited the power of our survival analyses and 
differed to the 40/60 split identified in the previous study on adult patients.  
IBD is a complex condition with a wide phenotypic spectrum, so age-related differences in gene 
expression profiles are likely, and previous studies have shown that children tend to develop a 
severe disease phenotype more often (and earlier) than adult patients. A common theme throughout 
our findings is that IBD in the paediatric population is less heterogeneous than that in the adult 
population: the majority of paediatric patients appear to suffer from moderate or severe forms of the 
disease and therefore fall into the same prognostic group.  
By comparing the clinical data collected to the information available from the adult study, we were 
able to provide evidence that paediatric IBD is a disease subgroup where the vast majority of patients 
fall into the moderate/severe group (Fig. 3.9 on page 69). 
Of particular interest are our findings related to the investigation of T-cell exhaustion in children. 
Exhaustion genes expressed in adults were mostly down-regulated in our paediatric cohort and vice 
versa. This may suggest that children go on to develop a severe disease course because their T-
cells are not exhausted. 
Because it was not possible to apply the prognostic power of adult signatures to the paediatric 
population, the second part of our work was based on testing for the existence of paediatric-specific 
signatures that could serve as prognostic biomarkers in children with IBD. Significant correlations 
were obtained by analysing CD and UC separately: signatures from specific WGCNA modules 
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generated noteworthy differences in use of biologics in CD and in surgical intervention in UC between 
the groups identified. 
GSEA based on the groups identified using the above signatures highlighted the presence of 
pathways including IL7, TNF-alpha and interferon, amongst others which are less known to play a 
role in IBD. However, the reliability of the paediatric signatures identified is such that further validation 
is required, as the correlation indexes ranged between ± 0.2 and ± 0.4 for most of the clinical 
outcomes investigated. 
Interestingly, the findings emerging from our study suggest that a smaller focus should be placed on 
the use of prognostic biomarkers in paediatric IBD. In fact, as the majority of children seem to fall in 
the severe prognostic group, one should recommend a top-down approach to enable prompt 
effective treatment in anticipation of further complications. Our results may question the worth of a 
biomarker for predicting the overall disease course in paediatric IBD, but the focus should remain on 
developing predictors of response to treatments, particularly in view of the development of new drugs 
on the horizon. A major interest in predicting the response to IBD treatment has recently arisen, and 
promising data is emerging 168.  
In summary, this prospective study performed on a large cohort and over an adequate follow-up 
time, has increased our understanding of paediatric (and adult) IBD by confirming that patients of 
paediatric age follow a more severe disease course, which makes the identification and validation of 
prognostic biomarkers particularly challenging. Paediatric IBD appears to be a unique entity with a 
more severe phenotype. 
Importantly, our findings pave the way to further investigation on the process of T-cell exhaustion in 
children. Exploring mechanisms that induce exhaustion of T lymphocytes might provide future 
preventative therapeutic options for paediatric patients diagnosed with IBD. 
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6.2 Strengths and limitations  
 
The main strength of this work is the prospective recruitment of a large cohort of treatment-naïve 
paediatric patients and the thorough collection of detailed clinical information from the same operator 
over a 1.5-year follow-up period.  
The consistent results found by using two complementary bioinformatics analyses, i.e. unsupervised 
clustering and WGCNA, are also an element of strength in supporting our findings and conclusion. 
The single-centre setting of the work is arguably a limitation, as it allowed a reliable, consistent, 
single-operator-based collection of detailed clinical data, which was fundamental for the aim of this 
specific study. 
Another limitation in this study was that the comparison between the paediatric and the adult gene 
expression data was managed by keeping the two cohorts separate. In fact, merging data from 
different versions of the gene expression array (Affymetrix Human Gene 1.0 and 2.0 ST, respectively) 
was not achievable. Nevertheless, we are planning to use whole blood samples collected in PAX 
tubes from a group of children from the same paediatric cohort to test the adult prognostic signature 
through a RT-PCR essay. This approach will allow us to bypass the issue of the different arrays and 
will be used as a validation step of our findings.  
In respect to limitations, this 4-year project acts as an example of the huge amount of translational 
work that is required for the development and/or testing of prognostic biomarkers. The availability of 
patients and samples, the prospective collection of clinical data including strict patient monitoring 
during follow-up (as shown in Appendix 2 on page 176), laboratory techniques (e.g. cell separation, 
extraction of nucleic acids, microarray), and the availability of bioinformatics skills for appropriate up-
to-date analyses all made this experience complex and challenging. 
One relevant hurdle in collecting clinical information was the identification of which parameters would 
reflect disease severity in a paediatric population. In fact, using the number of treatment escalations 
as in the adult study would be limiting in paediatric patients who mostly have more than two 
escalations. We therefore collected information on the use of biologics, IBD-related surgical 
intervention and IBD-related inpatient admissions in order to expand the outcome range and 
increase the chance of identifying a split between the more severe patients and the milder ones. In 
the absence of a summary score for disease severity in the paediatric literature to date, we also 
created scores for the purpose of this study, although they could not be weighted or validated 
(chapter 2.2.1 on page 45). 
In summary, the complexity mentioned above must be taken into account when setting up 
translational research studies aimed to develop disease biomarkers. We foresee that in the near 
future, more advanced and automated electronic clinical databases will alleviate the need for manual 
data collection. Moreover, new computational tools are likely to be implemented to match high 
throughput data with corresponding clinical information. 
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6.3 Future work 
 
We are currently using whole blood samples collected in PAX tubes from a group of 79 children 
enrolled in this study to test the adult prognostic signature through a RT-PCR assay, as a validation 
step of the work presented in this thesis. We aim to verify whether the majority of these children 
would correspond to the adult severe prognostic group, as expected from the findings of this study. 
If this were to be the case, the limited role of CD8+ gene expression signatures as disease prognostic 
biomarkers in paediatric patients would be corroborated. 
Additionally, we aim to complete and improve the preliminary work on CD8+ DNA methylation 
showed in chapter 5. Relevant findings have recently been published on the role of DNA methylation 
profiles in intestinal epithelial cells as diagnostic biomarkers for paediatric IBD, with specific changes 
in methylation reflecting the type of IBD diagnosis and its distribution 64,65.  
No data on DNA methylation profiles in CD8+ T-cell has been shown so far, to our knowledge. CD8+ 
methylation samples from a larger cohort are now available in our laboratory, hence we aim to 
conduct further bioinformatics analysis aimed to test this parameter as a potential prognostic 
biomarker in children with IBD. 
Future investigation should focus on T-cell exhaustion signatures. Findings from this study suggest 
that CD8+ T-cells in children might be not exhausted which may therefore predispose the patients 
to a more severe disease course. If such a theory were to be proved by further experiments, this 
would potentially pave the way towards preventative therapeutic options based on inducing T-cell 
exhaustion in paediatric-onset IBD. 
Finally, throughout the course of this project we have collected blood samples at different time points 
during the patients’ follow-up, i.e. when patients were being treated and were either achieving 
remission or going through a relapse of their IBD. Analysis of gene expression (and methylation) 
profiles from these samples and correlation with clinical data has the potential to measure the 
stability of these profiles over time and their correlation with disease activity and/or response to 
treatments.  
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Appendix 1. Definition, measurement units and normal values of the main clinical 
items collected 
 
• IBD diagnosis: The sub-classification of the IBD-U as CD-like or UC-like was based on the 
combination of disease localisation (e.g. the involvement of any tract of the small bowel would be 
more consistent with CD, with the exception of backwash ilieitis in patients with UC) and of the 
histological findings 2; 
• Diarrhoea at diagnosis: defined by the World Health Organisation as having three or more loose 
or liquid stools per day; diarrhoea is defined as chronic when symptoms last more than 14 days; 
• Stool consistency at diagnosis: scores 1 to 7, as defined by the Bristol Stool Scale; 
• Moderate-severe abdominal pain, defined as > 5 on VAS Scale; 
• Weight loss at diagnosis: defined as an involuntary loss ≥ 10% of the weight reported before the 
symptom onset; 
• Fever at diagnosis: defined as T> 37.5 ^C with no detection of infections; 
• Iron deficiency anaemia at diagnosis: definition based on the combination of clinical signs and 
symptoms, RBC count, haematocrit, haemoglobin, MCV, reticulocytes, ferritin levels. 
Haemoglobin thresholds as defined by World Health Organisation: 11 g/dL for children < 5 years 
of age, 11.5 g/dL for children aging 5-10 years, 12 g/dL for children aging 12 – 15 years; 
• Perianal disease at diagnosis (fissures, fistulae, abscesses) defined on the basis of clinical 
assessment ± pelvis MRI); 
• Extraintestinal manifestations (EIMs) at diagnosis: joint pain, hepato-biliary disorders (diagnostic 
work-up based on clinical evidence of liver enlargment and/or jaundice, liver function tests, 
serology, imaging ± ERCP), pancreatitis (diagnostic work-up based on clinical assessment, 
measurement of pancreatic enzymes, imaging), skin manifestations (erythema nodosum, 
pyoderma gangrenosum), eye manifestation (uveitis, epi-scleritis); 
• Mouth ulcers: considered when detected at diagnosis or during the recent months prior to 
diagnosis; 
• Scores of IBD activity at diagnosis and at follow-up: Paediatric Crohn's Disease Activity Index 
(PCDAI) and Paediatric Ulcerative Colitis Activity Index (PUCAI) 34-35; 
• Disease localisation at diagnosis and at follow-up: defined according to the Paris classification for 
IBD 13 (Appendix 6 on page 1208), on the basis of endoscopy, histology and small bowel MRI 
results; 
• White Blood Cells (WBC) at diagnosis and at follow-up (x 10^3/mm3, n.v. ages 5 to 12 years: 
males 4.5-10.5, females 4.7-10.3; ages 12 to 16 years: males 4.5-10, females 4.8-10.1); 
• Haemoglobin (Hb) at diagnosis and at follow-up (g/dL, n.v. ages 5 to 12 years: males 11-13.3, 
females 10.9-13.3; ages 12 to 16 years: males 11.5-14.8, females 11.2-13.6); 
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• Mean Corpuscolar Volume (MCV) at diagnosis and at follow-up (fL, n.v. boys: 78 – 98, girls: 78 – 
102); 
• Haematocrit (Htc) at diagnosis and at follow-up (%. n.v. ages 5-12 years: males 32.7-39.3, 
females 33-39.6; ages 12-18 years: males 34.8-43.9, females 34-40.7); 
• Platelet count at diagnosis and at follow-up (x 10^3/mm3, n.v. ages 5 to 12 years: males 194-364, 
females 183-369; ages 12 to 18 years: males 165-332, females 185-335); 
• C-reactive protein (CRP) at diagnosis and at follow-up (mg/L, n.v. < 6); 
• Erythrocyte sedimentation rate (ESR) at diagnosis and at follow-up (mm/h, n.v. < 8 mm/h); 
• Albumin at diagnosis and at follow-up (g/L, n.v. ages 5 to 6 years: 35-52; ages 7 to 9 years: 37-
56; ages 9 to 19 years: 37-56); 
• Faecal calprotectin at diagnosis and at follow-up (mcg/g, threshold for significance 300). 
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Appendix 2. Clinical Database used as a .csv file to align clinical data to gene 
expression data in the WGCNA. 
 
Case 
Number Gender Diagnosis 
Age at 
diagnosis 
Family 
history of 
IBD 
Z score for 
Weight at 
diagnosis 
6.CEL 1 0 12 0 -0.817 
10.CEL 1 1 15 0 -2.469 
13.CEL 1 1 13 0 -0.441 
16.CEL 0 0 13 1 -0.364 
19.CEL 1 1 10 0 -1.255 
21.CEL 0 0 14 0 -0.824 
24.CEL 0 0 14 0 1.795 
26.CEL 1 1 13 0 -1.71 
28.CEL 0 0 14 0 1.208 
30.CEL 1 0 12 0 0.7 
34.CEL 0 1 13 0 0.729 
40.CEL 1 0 14 1 -0.872 
44.CEL 1 1 13 0 -1.254 
46.CEL 0 0 11 0 1.367 
47.CEL 1 0 13 0 -0.491 
49.CEL 1 1 10 0 -0.239 
50.CEL 1 1 8 1 0.45 
51.CEL 1 1 13 0 -1.13 
53.CEL 0 0 7 1 -0.372 
57.CEL 1 0 12 0 0.066 
58.CEL 0 1 13 0 0.935 
59.CEL 0 1 8 0 -1.437 
61.CEL 1 1 15 0 0.848 
70.CEL 1 1 13 1 -0.029 
72.CEL 1 1 7 0 -0.981 
74.CEL 1 0 14 1 -0.757 
76.CEL 1 1 14 0 0.328 
77.CEL 0 1 14 0 -0.381 
78.CEL 1 1 14 0 -0.53 
80.CEL 0 0 14 0 -0.316 
82.CEL 1 1 14 1 -0.427 
83.CEL 1 0 13 1 0.779 
84.CEL 1 1 17 0 -0.28 
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89.CEL 0 0 10 0 -0.234 
90.CEL 1 1 9 1 -0.633 
91.CEL 0 0 6 1 2.16 
92.CEL 0 0 9 0 0.674 
93.CEL 1 0 9 0 -0.16 
95.CEL 1 1 6 0 -0.12 
96.CEL 0 0 15 0 0.175 
97.CEL 1 1 13 0 -1.91 
98.CEL 0 1 15 0 -0.98 
102.CEL 0 1 11 0 -0.37 
104.CEL 1 1 15 0 -1.65 
105.CEL 1 1 13 0 -2.09 
106.CEL 1 1 11 0 -0.02 
112.CEL 1 1 13 0 0.95 
116.CEL 1 0 8 0 1 
173.CEL 1 1 13 1 0.76 
174.CEL 1 0 14 0 -0.56 
193.CEL 1 1 14 1 0.4 
199.CEL 1 1 13 0 -2.03 
205.CEL 1 1 14 1 0.64 
206.CEL 0 0 15 0 1.65 
208.CEL 1 0 12 0 -0.27 
209.CEL 0 1 13 1 -1 
217.CEL 1 1 14 0 0.73 
219.CEL 1 1 11 0 1.52 
227.CEL 1 1 13 0 -2.33 
232.CEL 0 1 15 0 -2.65 
236.CEL 0 0 11 1 -0.21 
246.CEL 1 1 13 1 -0.43 
249.CEL 1 1 13 1 -1.49 
251.CEL 0 0 11 0 1 
270.CEL 1 1 12 0 -0.68 
272.CEL 1 1 15 1 -1.66 
273.CEL 0 1 9 0 2.27 
277.CEL 1 1 11 1 -0.07 
279.CEL 1 1 12 0 1.38 
280.CEL 0 1 15 1 1.69 
282.CEL 0 1 12 0 -0.76 
289.CEL 1 1 10 0 0.39 
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290.CEL 0 1 15 0 -2.75 
301.CEL 1 1 7 0 1.08 
307.CEL 0 1 15 0 -0.26 
310.CEL 1 0 11 0 0.88 
318.CEL 0 1 10 0 -1.04 
319.CEL 0 1 9 0 -1.12 
320.CEL 1 1 11 0 -0.429 
321.CEL 0 0 13 0 -0.69 
323.CEL 1 0 15 1 -0.67 
324.CEL 1 0 11 1 1.12 
330.CEL 0 1 15 1 -0.85 
335.CEL 0 1 14 1 -1.04 
340.CEL 1 0 15 0 -0.73 
344.CEL 1 0 15 0 0.69 
348.CEL 0 1 11 0 -1.4 
352.CEL 0 1 15 0 -0.24 
354.CEL 1 1 15 0 -2.21 
358.CEL 1 1 13 0 -1.79 
359.CEL 1 1 13 0 -0.5 
360.CEL 0 0 8 0 -1.36 
366.CEL 1 0 12 1 1.03 
370.CEL 0 0 14 1 -1.209 
376.CEL 0 0 15 0 1.03 
385.CEL 1 0 5 0 -3.08 
387.CEL 1 0 14 0 2.01 
392.CEL 0 0 15 0 0.68 
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Z score for 
Height at 
diagnosis 
Abdominal 
pain at 
diagnosis 
Diarrhoea at 
diagnosis 
Mucus in 
stools at 
diagnosis 
Per rectal 
bleeding at 
diagnosis 
Weight loss 
at 
diagnosis 
-1.155 1 1 0 0 1 
0.988 1 1 0 0 1 
1.368 1 1 0 1 1 
0.26 0 1 1 1 1 
-0.111 1 1 1 1 1 
0.317 1 1 0 0 0 
0.779 1 1 0 1 0 
-1.572 0 1 0 1 1 
0.316 1 1 1 1 0 
0.7 1 1 1 1 0 
0.617 1 1 0 1 0 
0.357 1 0 0 1 1 
-1.164 1 1 0 0 0 
-0.437 1 0 0 1 0 
0.465 1 1 0 1 0 
1.234 1 1 0 0 1 
0.3 1 0 0 1 0 
-0.27 1 0 0 1 1 
-0.864 1 1 0 1 0 
0.615 1 1 0 1 0 
1.464 0 1 0 1 0 
-1.838 1 1 0 0 0 
1.159 1 1 0 0 1 
1.83 1 1 1 1 1 
-1.485 0 0 0 0 1 
-0.412 0 1 0 1 0 
-0.334 1 0 0 1 0 
0.351 1 1 1 0 0 
0.646 1 1 1 1 0 
-0.854 0 0 0 1 0 
1.728 1 1 0 1 0 
-1.141 0 1 0 1 0 
0.381 1 0 0 1 1 
-0.451 1 1 0 0 0 
-1.726 1 1 0 1 0 
2.306 1 1 1 1 0 
 180 
1.009 1 1 1 1 0 
-1.987 1 1 0 1 0 
0.723 0 1 0 0 1 
-0.369 1 1 0 1 1 
-0.77 1 0 0 0 1 
0.07 1 1 0 1 1 
0.58 1 1 0 1 0 
-0.2 1 1 0 1 1 
-1.6 1 1 0 0 1 
0.79 1 1 0 0 0 
-0.82 1 0 0 1 0 
1.56 1 1 0 1 0 
0.25 1 0 0 0 0 
-0.85 1 1 0 1 1 
-0.15 1 1 0 1 0 
-0.73 1 1 1 0 1 
1.36 0 0 0 0 0 
-0.17 0 1 0 1 0 
-0.99 0 0 0 1 0 
-0.77 1 1 0 1 0 
1.07 1 1 0 1 1 
1.32 1 1 1 0 0 
-1.8 1 0 0 0 0 
-0.75 0 1 1 1 1 
-0.14 1 1 1 1 0 
-0.03 1 1 1 1 0 
0.13 1 1 1 1 1 
0.48 1 1 0 1 0 
0.18 1 1 0 0 0 
-1.03 1 1 0 1 1 
0.93 1 0 0 1 0 
0.31 1 1 0 0 0 
0.83 0 1 0 1 0 
1.5 1 1 1 0 1 
0.25 1 0 0 0 1 
1.41 1 0 0 0 1 
-2.24 1 1 1 0 1 
-0.02 1 1 0 1 0 
-0.02 1 1 0 0 1 
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1.43 1 1 0 1 0 
0.49 1 1 0 1 1 
0.2 1 0 0 0 1 
0.568 1 1 0 0 1 
-0.86 1 1 0 1 0 
-0.03 1 1 0 1 0 
0.93 1 1 1 1 0 
0.36 1 0 0 1 1 
-0.75 1 1 0 1 1 
-0.1 0 1 0 1 0 
0.69 1 1 1 1 0 
-0.88 1 0 0 0 0 
-0.14 1 0 1 1 0 
-0.85 1 1 0 1 1 
-0.81 1 1 0 1 1 
-0.45 0 1 1 1 0 
0.04 1 1 0 1 0 
0.14 0 1 0 1 1 
-0.168 1 1 0 1 0 
1.28 1 0 0 1 1 
-1.49 0 0 0 1 1 
0.91 0 1 0 1 0 
0.23 1 1 1 1 1 
 
  
 182 
Nocturnal 
symptoms 
at 
diagnosis 
Nausea / 
vomiting at 
diagnosis 
Urgency / 
tenesmus 
at 
diagnosis 
Lethargy at 
diagnosis 
Iron 
deficiency 
anaemia at 
diagnosis 
Mouth 
ulcers at 
diagnosis 
0 0 1 1 0 0 
0 0 0 1 1 1 
0 0 0 0 0 1 
0 0 0 0 1 0 
0 0 0 0 1 0 
1 0 0 0 0 0 
1 0 0 0 0 1 
0 0 0 0 0 1 
0 0 0 0 0 0 
1 1 1 0 0 0 
0 0 1 0 1 1 
1 0 1 0 0 0 
1 0 1 1 0 0 
0 0 0 0 0 0 
0 0 0 0 0 0 
0 0 0 0 0 0 
0 0 0 1 0 0 
0 1 0 0 0 1 
0 0 0 0 0 0 
1 0 1 0 0 0 
0 0 0 0 0 0 
0 1 1 1 0 1 
0 1 0 1 0 0 
0 0 0 0 0 0 
0 0 0 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
1 0 0 1 0 0 
0 0 0 0 0 0 
0 0 0 0 0 0 
1 0 0 0 0 0 
0 0 0 0 0 0 
0 0 0 1 1 1 
1 0 0 1 0 0 
0 0 0 0 0 0 
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0 0 1 0 0 0 
0 0 0 0 0 0 
1 0 0 0 0 0 
1 0 0 1 0 0 
0 0 0 0 0 0 
0 0 0 0 0 0 
1 0 1 0 0 0 
0 0 0 1 0 0 
0 0 0 0 0 0 
0 0 1 1 0 0 
0 0 0 0 0 0 
0 0 0 0 1 0 
1 0 0 0 1 0 
1 1 0 0 0 0 
0 0 0 0 0 0 
0 0 0 1 0 0 
0 1 0 0 0 0 
0 1 1 0 0 0 
0 0 0 1 1 0 
0 0 0 0 0 0 
0 1 0 1 0 0 
0 0 0 0 0 0 
0 0 1 1 0 0 
0 1 0 1 0 0 
0 1 1 1 0 1 
0 0 0 1 0 0 
0 0 0 1 1 0 
1 0 1 0 0 0 
0 0 1 0 1 0 
0 0 0 1 0 1 
1 0 0 1 1 0 
0 0 0 0 0 1 
1 1 0 1 0 0 
0 0 0 1 0 1 
0 1 0 0 0 0 
1 0 0 1 0 0 
0 0 0 1 0 0 
1 1 1 1 1 0 
1 0 1 0 0 0 
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0 0 0 0 0 0 
0 1 0 0 0 0 
0 0 0 0 0 0 
0 1 0 1 1 0 
0 0 0 1 1 0 
0 0 0 0 0 0 
0 0 1 0 0 0 
1 0 1 0 0 0 
0 1 1 0 1 0 
0 1 0 1 0 0 
1 0 1 0 0 0 
0 0 0 0 0 0 
0 0 0 0 0 1 
0 0 0 1 1 0 
0 1 0 1 1 0 
1 0 0 1 1 0 
0 0 0 0 0 0 
0 0 0 1 1 0 
1 0 1 0 0 0 
0 0 1 0 0 0 
0 0 0 0 0 0 
0 0 1 0 1 0 
0 0 1 0 0 0 
0 0 0 0 1 0 
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Joint pain at 
diagnosis 
Fever at 
diagnosis 
Time onset 
to 
diagnosis  
Perianal disease 
at diagnosis 
Liver 
involvement 
at diagnosis 
EIM at 
diagnosis 
0 0 3 0 0 0 
0 0 1 1 0 0 
1 1 2 0 0 0 
0 0 2 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
0 0 2 1 0 0 
1 0 2 0 0 0 
0 0 1 0 0 0 
0 0 3 0 0 0 
0 0 1 0 0 0 
0 0 3 0 1 1 
0 0 3 0 0 0 
0 0 3 0 0 1 
0 0 3 0 1 0 
0 0 3 0 0 0 
1 0 2 0 0 1 
0 0 3 0 0 0 
0 0 1 0 0 0 
0 0 3 0 0 0 
1 1 1 0 0 1 
0 0 3 0 0 0 
0 0 1 0 0 0 
0 0 3 1 0 0 
0 0 3 1 0 0 
0 0 2 0 0 0 
0 0 1 0 0 1 
1 0 3 0 0 1 
0 0 3 0 0 0 
0 0 2 0 0 1 
0 0 1 0 0 0 
0 0 3 1 0 0 
0 1 2 0 1 0 
0 0 3 0 0 0 
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0 0 3 0 0 0 
0 0 2 0 0 0 
0 0 1 0 0 0 
0 0 1 1 1 0 
0 0 2 0 0 0 
0 0 2 0 0 1 
0 0 1 1 1 0 
1 0 1 0 0 0 
0 0 3 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
1 0 2 0 0 1 
0 0 2 0 1 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
0 0 3 1 0 0 
0 0 1 0 0 0 
1 0 3 0 0 1 
0 0 2 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
0 0 2 0 0 0 
0 0 3 0 0 1 
1 0 1 0 0 1 
0 0 2 0 0 0 
0 0 1 0 0 0 
0 0 2 0 0 0 
0 0 3 0 0 0 
1 0 1 0 0 0 
0 0 1 0 0 0 
0 0 2 0 0 0 
1 0 1 1 0 1 
0 0 2 0 1 0 
0 0 2 0 0 0 
0 0 2 0 0 0 
0 0 2 0 0 0 
0 0 2 0 0 0 
0 0 3 0 0 0 
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0 0 2 0 0 0 
0 1 1 0 0 0 
0 0 3 0 1 0 
0 0 2 0 0 0 
0 0 1 0 0 0 
0 0 3 0 0 0 
0 0 3 0 0 0 
0 0 1 0 0 0 
0 1 3 0 0 0 
0 0 3 1 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
0 0 3 0 0 1 
1 0 1 1 0 1 
0 0 1 0 0 0 
0 0 2 0 0 0 
0 0 3 0 0 0 
0 0 2 0 0 0 
0 0 2 0 0 0 
0 0 2 0 1 0 
0 0 3 0 0 0 
0 0 2 0 0 0 
0 0 1 0 0 0 
0 0 1 0 0 0 
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Growth 
deficiency at 
diagnosis 
White Cell 
Count at 
diagnosis 
(x 10^3 / 
mm3) 
Haematocrit 
at 
diagnosis 
(%) 
Platelets at 
diagnosis (x 
10^3 / mm3) 
Ferritin at 
diagnosis (ug 
/ L) 
ESR at 
diagnosis 
(mm / h) 
0 8.6 30.9 460 15 38 
0 12.3 36.8 579 12.4 25 
0 5.5 41.7 366 39.2 30 
0 7.3 32.6 341 33.4 8 
1 12.3 24.7 796 1.8 47 
0 7.7 36.2 633 2.5 17 
0 7.2 34.7 226 16.7 19 
0 9.8 36.6 538 40.2 25 
0 9.3 38 277 23.7 11 
0 10.6 37.5 397 4.6 9 
0 5.7 32.2 304 21.3 8 
0 7.2 39.5 280 3.6 16 
0 7.9 26.8 538 20 49 
0 7.4 34.1 273 14 7 
0 8.8 34.6 376 13.7 18 
0 10.8 39.9 303 15 18 
0 8.7 39 309 66.2 6 
1 6.7 35.6 328 99.5 13 
0 11.3 33.6 427 15 9 
0 6.9 35.6 409 21 16 
0 5.9 37.6 259 15 15 
1 22.3 26.3 613 156.8 35 
0 8.2 37.5 464 10 16 
0 10.5 33.4 442 11.9 13 
1 12.8 37.7 400 39 8 
0 9 39 251 6.1 4 
0 6.8 36.1 350 10.3 33 
0 8.7 29.2 483 6.5 32 
0 9 37.3 187 7.7 11 
0 6.7 37.3 309 3.6 14 
0 9.3 38.1 490 269.8 79 
0 7.7 41.6 186 27.9 4 
1 6 33.9 421 10 30 
0 21.2 31.2 574 7 65 
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0 7.4 37 340 10 6 
0 8.6 33 330 6.5 12 
0 8.1 41.1 256 36.5 5 
0 14.8 20.8 348 2.5 54 
1 13.2 33.2 475 5.1 19 
0 8.7 34.2 289 12.5 18 
0 14.5 35.2 692 8.8 25 
0 6 30 371 28.7 10 
0 8.5 29 336 1 6 
0 8 35.2 380 15 10 
0 12.6 37.8 541 155.8 5 
0 8.4 36.6 463 10.4 10 
0 8.1 37.8 342 17.6 16 
0 8.1 39.5 369 14.6 29 
0 16.5 31.5 693 118.6 29 
0 9.2 29 267 14.6 10 
0 10.1 37.3 334 132.6 33 
0 11.6 37.2 710 66 17 
0 5.3 45 296 17 4 
0 9.4 36.5 394 4.6 10 
0 8.2 34.8 273 6 7 
0 7.5 32.3 548 14 34 
0 6 31.2 610 22 47 
0 10.9 38.4 322 34.9 13 
0 7.3 30.3 356 31.4 35 
0 3.6 40.3 304 95 42 
0 8.1 37 299 12.3 5 
0 8 35.4 367 15 12 
1 8.2 36.3 503 56.5 10 
0 11.8 34 576 6.7 44 
0 8.4 40.3 266 6.2 5 
0 12.6 34.2 364 146.1 17 
0 6.6 36.4 374 15 22 
0 9.1 35.7 482 96 19 
0 5.8 31.4 386 5.7 54 
0 6.2 36.8 228 15 6 
0 7.1 38.8 494 42.4 39 
1 12.8 37.5 537 86 43 
1 13.4 37 82 10.8 82 
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0 8.2 41 547 15 9 
0 7.8 39.5 373 62.1 7 
0 6.3 42.5 656 15 9 
0 8.1 41.2 420 10.7 1 
0 9.1 33 523 30.7 39 
0 6.5 38.7 279 12.9 26 
0 6.8 33.1 359 11.3 16 
0 6.8 37.5 373 5.7 5 
0 10.5 34 503 5.9 16 
0 5.5 31.8 359 26.6 33 
0 5.1 35.1 527 9.6 19 
0 5.2 43.6 325 9 15 
0 6.1 44.4 220 84.5 5 
0 7.8 40.2 243 27.6 10 
1 11.8 34.6 290 18 25 
0 7.4 34.1 476 73.4 30 
1 12.3 36 645 72.9 42 
0 8 34.2 366 19 16 
0 8.6 27.6 721 15 32 
0 13 35 307 4.6 9 
0 4.7 34.4 339 23.6 32 
0 5.5 29.9 283 3.1 28 
0 6.8 32 409 15 29 
0 4.7 42.5 245 20.4 4 
0 9 24.5 532 19.5 44 
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CRP at 
diagnosis 
(mg/L) 
Albumin at 
diagnosis 
(g/L) 
ALT  at 
diagnosis 
(U/L) 
GGT at 
diagnosis (U/L) 
Disease 
activity at 
diagnosis 
(PCDAI/PUCAI) 
Number of 
treatment 
escalations 
1 39 27 24 22.5 1 
71 27 14 60 42.5 1 
3 36 46 21 30 0 
1 33 19 20 30 3 
22 21 15 26 55 3 
6 33 17 21 40 0 
7 41 41 58 45 1 
31 30 17 16 35 3 
2 41 18 21 35 3 
30 31 18 31 55 1 
30 28 24 14 37.7 2 
4 34 16 21 45 2 
64 25 25 60 50 5 
2 40 21 25 35 3 
3 43 40 29 30 3 
3 41 257 147 25 0 
4 41 19 11 20 2 
56 19 10 23 40 3 
5 36 23 18 35 1 
1 37 15 19 45 0 
1 44 10 10 12.5 0 
101 27 16 11 47.5 4 
49 30 27 40 30 0 
23 27 12 7 37.5 1 
1 31 12 7 17.5 0 
1 45 15 18 22.5 2 
18 37 11 9 20 1 
41 26 9 14 42.5 2 
12 36 13 9 25 0 
1 40 9 7 17.5 0 
150 35 10 13 27.5 0 
4 39 15 20 20 1 
53 29 16 13 40 0 
128 30 28 24 52.5 3 
1 30 12 6 30 4 
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3 38 21 14 45 1 
4 46 19 14 30 1 
1 35 8 9 45 1 
5 34 27 197 35 3 
8 38 9 9 30 3 
14 29 10 10 27.5 2 
20 27 15 10 37.5 3 
4 41 15 27 32.5 3 
34 41 15 10 30 3 
48 32 8 11 35 2 
21 36 10 11 25 0 
19 31 18 7 25 1 
4 35 54 28 50 1 
40 40 8 42 15 2 
4 37 10 8 20 0 
23 36 19 54 25 3 
23 32 11 10 25 0 
2 39 15 15 15 1 
4 39 18 15 30 1 
4 38 15 7 20 2 
33 27 9 10 40 1 
30 35 9 13 35 1 
20 34 20 30 35 2 
79 26 8 14 30 1 
84 26 5 11 32.5 1 
4 43 21 12 15 1 
7 41 13 12 30 3 
12 29 11 34 45 4 
4 32 11 9 25 1 
17 39 14 8 27.5 1 
101 24 8 16 37.5 3 
15 38 17 10 17.5 0 
8 30 24 18 35 4 
4 37 66 129 45 0 
4 46 15 17 25 1 
37 39 11 12 35 2 
22 33 10 8 32.5 2 
74 38 17 15 35 1 
4 38 31 20 15 0 
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4 42 12 18 25 0 
4 35 12 10 55 3 
4 35 14 16 55 2 
29 27 10 36 32.5 3 
11 30 16 15 35 1 
6 39 10 12 50 0 
8 34 13 12 40 0 
6 37 17 7 60 4 
4 35 11 12 35 3 
18 19 8 8 37.5 4 
12 45 18 17 50 0 
4 44 22 34 50 2 
4 39 17 12 15 0 
8 32 42 26 22.5 2 
28 30 40 48 35 2 
74 31 8 17 35 1 
10 36 11 14 20 2 
10 37 15 11 45 1 
4 38 19 10 50 0 
4 39 19 31 45 1 
4 38 15 7 40 1 
5 36 13 8 45 1 
4 43 26 12 40 0 
3 37 9 18 65 1 
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Use of 
biologics 
Surgical 
intervention 
Steroid 
resistance / 
dependency 
6 months 
steroid free 
remission 
Number of 
relapses 
Number of 
endoscopies 
0 0 0 0 1 1 
0 0 0 0 2 2 
0 0 0 0 0 1 
0 0 0 1 3 2 
1 0 0 0 3 2 
0 0 0 1 1 1 
0 0 0 0 2 2 
1 0 0 1 4 2 
0 0 1 0 3 1 
0 0 0 1 2 1 
0 0 0 0 3 1 
0 0 0 1 2 1 
1 0 0 0 4 3 
0 0 1 0 4 4 
0 0 1 1 3 3 
0 0 0 1 0 1 
0 0 0 1 1 3 
1 0 1 1 3 2 
0 0 0 1 1 1 
0 0 0 1 0 1 
0 0 0 1 0 2 
1 0 1 0 4 3 
0 0 0 1 0 1 
0 0 0 0 1 2 
0 0 0 1 0 1 
0 0 0 1 2 2 
0 0 0 1 1 2 
1 0 0 0 2 2 
0 0 0 0 0 1 
0 0 0 1 0 1 
0 0 0 1 0 1 
0 0 0 1 2 2 
0 0 0 1 1 1 
1 1 0 0 4 2 
1 0 1 0 4 4 
0 0 0 1 1 1 
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0 0 0 0 1 1 
0 0 0 0 1 2 
1 0 1 1 3 3 
1 0 1 0 3 2 
1 0 1 0 2 2 
1 0 0 0 2 2 
1 0 0 0 3 2 
1 0 1 0 4 4 
1 0 1 0 2 2 
0 0 0 1 0 1 
1 0 1 1 1 3 
0 0 0 0 1 2 
0 1 0 1 1 2 
0 0 0 1 0 1 
1 0 1 0 3 2 
0 0 0 1 0 1 
0 0 0 0 1 1 
0 0 0 1 1 2 
0 0 0 0 2 3 
0 0 0 1 1 2 
0 0 0 1 1 1 
0 0 0 0 3 3 
0 0 0 0 1 1 
1 0 0 0 1 2 
0 0 0 1 1 2 
1 0 1 0 3 2 
1 0 1 0 4 3 
0 0 0 1 0 1 
0 0 0 1 0 1 
1 0 1 0 4 2 
0 0 0 1 0 1 
1 0 1 1 3 2 
0 0 0 1 0 1 
0 0 0 1 0 1 
1 0 1 0 2 2 
0 0 0 0 3 2 
0 0 0 1 1 3 
0 0 0 1 0 1 
0 0 0 1 0 1 
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1 1 1 0 4 2 
1 0 1 0 3 3 
1 0 1 0 3 2 
0 0 0 1 1 1 
0 0 0 1 0 1 
0 0 0 1 0 1 
1 0 0 0 4 1 
1 0 1 0 4 3 
1 0 1 0 4 2 
0 0 0 1 0 1 
0 0 1 1 2 1 
0 0 0 1 0 1 
0 0 0 0 2 1 
0 0 0 0 2 1 
1 0 0 0 1 2 
0 0 0 0 1 2 
0 0 0 0 1 1 
0 0 0 1 0 1 
0 0 0 1 1 1 
0 0 0 0 1 1 
0 0 0 0 1 1 
0 0 0 1 0 1 
0 0 0 0 1 1 
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Number of 
unplanned 
inpatient 
days 
Num of 
outpatient 
days 
Severity 
Score 
School 
attendance 
Psychological 
support 
0 11 2 1 1 
0 13 1 1 1 
0 9 0 1 0 
5 15 4 1 1 
10 15 6 0 1 
0 9 0 1 1 
0 16 2 1 1 
0 23 5 1 1 
0 11 4 0 0 
0 17 1 1 0 
0 13 1 1 0 
0 6 3 1 0 
7 24 6 0 1 
0 22 4 0 1 
0 15 2 1 0 
0 10 0 1 0 
0 17 1 0 0 
3 15 5 0 1 
0 5 0 1 0 
0 7 0 1 0 
0 9 0 1 0 
12 24 6 0 0 
0 13 0 1 0 
0 18 0 1 0 
0 12 1 1 0 
1 7 1 1 0 
1 9 0 1 0 
0 13 3 1 0 
0 6 0 1 0 
0 4 0 1 0 
0 5 0 1 0 
0 6 0 1 0 
0 6 1 1 0 
8 15 10 0 1 
 6 5 1 0 
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0 5 2 1 0 
0 8 2 1 0 
0 9 2 0 0 
0 18 5 1 0 
0 11 6 1 1 
0 17 3 1 0 
2 18 5 0 1 
5 8 6 1 0 
20 21 6 1 0 
0 15 3 0 0 
0 8 0 1 0 
0 10 2 0 1 
0 8 2 0 0 
18 12 5 0 1 
0 5 0 1 0 
6 11 7 1 1 
0 9 0 1 0 
0 10 0 1 0 
0 11 0 1 0 
0 12 3 1 0 
0 10 0 1 1 
0 8 0 1 0 
10 13 3 1 0 
0 18 0 1 0 
0 13 2 1 0 
0 13 0 1 1 
0 18 4 1 0 
12 17 6 0 1 
5 9 2 0 1 
0 11 0 1 0 
10 21 6 0 0 
0 6 0 0 0 
0 13 5 0 0 
0 9 0 1 0 
0 8 0 1 0 
0 17 3 0 1 
0 13 1 1 0 
4 14 1 0 0 
0 7 0 0 1 
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0 5 0 1 0 
17 15 10 0 1 
11 18 5 0 1 
7 16 6 1 0 
0 13 0 0 1 
0 13 0 1 1 
0 12 0 1 0 
5 11 8 0 1 
2 19 4 0 1 
0 15 5 1 0 
0 8 0 1 0 
0 11 1 1 0 
0 4 0 1 0 
0 9 3 0 1 
3 8 2 0 0 
2 18 3 0 1 
0 12 1 1 1 
4 11 3 1 0 
0 8 0 1 1 
0 9 0 1 0 
3 12 2 1 1 
0 8 1 1 0 
0 8 0 1 1 
7 6 4 0 0 
 
Appendix 2 Legend: 0= event never happened; 1= event has happened; Gender: 0=female, 1=male; 
Diagnosis: 0=UC, 1=CD; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; time onset-diagnosis: 
1= < 3 months, 2= 3-6 months, 3= > 6 months. 
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Appendix 3. Protocols for CD8+ T cell separation (including MACS) (A), and 
preparation of samples for purity assessment (FACS) (B) 
 
Recipes 
 
1.  MACs Running Buffer (1 X PBS, 2mM EDTA, 0.5% BSA) 
4ml 0.5M EDTA 
50ml 10% BSA Stock 
Make up to 1 litre with 1xPBS. Filter Sterilise.  
 
2.  MACs Rinsing buffer (1xPBS 2mM EDTA) 
996ml  1xPBS 
4ml      0.5M EDTA 
Filter Sterilise. 
 
3.  MACs Cleaning Solution (70% Ethanol) 
 700ml absolute ethanol 
 300ml MilliQ water 
 
4.  Red Blood Cell Lysis Buffer 
0.155M  NH4Cl   [8.29g]  
12mM    NaHCO3  [1.0g] 
0.1M 0.5M EDTA    [200μl] 
Make up to 1 litre with distilled water (Store at 4ºC) 
 
5. 4% Sodium Citrate Solution 
40g of sodium citrate made up to 1l with sterile MilliQ water. 
 
6. FACs Fixative solution (only use when don’t have access to FACs) 
12.5ml 40% formaldehyde 
10g glucose 
5ml 2% Azide 
Make up to 500ml with sterile PBS. Filter sterilise and store at room temperature. 
 
A) CD8+ T cell separation from samples of peripheral blood 
 
1. Set up ficoll gradient tubes (as indicated below): Pipette 15ml of Histopaque 1077 into the falcon tubes 
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2. Collect appropriate volume of whole blood into 1x 50 ml Falcon tubes containing 4% sodium citrate 
solution and mix well by inversion. 
 
Age of the patient Volume of Blood (ml) 
 
Volume of 4% sodium citrate 
(1ml/10ml of blood) 
5-10 years 10 1 
10-16 25 2.5 
 
3. Aliquot 500ul of whole blood for DNA extraction. Put on ice. Store at -80C at the end of the protocol.  
 
4. Transfer the rest of the blood to T25 flask. Add appropriate volume of rinsing buffer at room 
temperature (RT) and mix well. 
Age of the patient Volume of Blood (ml) 
 
Volume of rinsing 
buffer(ml) 
5-10 years 10 5 
10-16 25 12.5 
 
5. Pipette diluted blood into syringe sitting in ficoll gradient tube with 19 gauge (yellow) needle with 
bevelled edge positioned as in diagram above. Ensure each tube has the same volume.  Layer no 
more than 35ml diluted blood over the histopaque. 
 
6. Centrifuge at 1900 rpm for 20 minutes at RT with the brake off. 
 
Age of the patient No. of falcon 
tube with Ficoll 
5-10 years 1 
10-16 2 
19 gauge needle 
 202 
Blood cell separation 
 
 
7. Using a 5ml pipette transfer the plasma (top layer) from tube into a 15ml Falcon tube (maximum 
3ml/tube), taking care not to disturb PBMC interface. Store at - 80ºC.  
8. Using a plastic Pasteur pipette remove the PBMC interface and transfer to a fresh 50 ml tube sitting 
on ice. Collect most of the Ficoll and the plasma layer. Make the volume up to 50 ml with rinsing buffer 
chilled to 4°C and mix by inversion. 
9. Centrifuge at 2000 rpm for 10 minutes at 4ºC with the brake on. 
10. Whilst PBMC tubes are spinning: using a pastette carefully remove any remaining ficoll layer from red 
blood cell pellet; dispose of the ficoll in the jar of virkon. Add 25 ml chilled red cell lysis buffer to the 
pellet. Mix well by inversion and incubate on ice for 30 minutes. 
11. Proceed to CD8+ T cell isolation and granulocyte separation protocol. 
 
CD8+ T cell (from PBMC) isolation 
 
12. Decant the supernatant from the PBMC tube into Virkon jar and disperse the cell pellets by flicking 
the tubes. 
13. Re-suspend each cell pellet in 25 ml rinsing buffer chilled to 4°C.   
14. Pool two tubes into one 50 ml Falcon tube 
15. Centrifuge 1000-1250rpm for 7-10 minutes at 4ºC with the brake on (soft spin which leaves the 
platelets in suspension). 
16. Decant the supernatant, disperse the cell pellets by flicking and re-suspend in 25 ml rinsing buffer 
chilled to 4°C.  
17. Centrifuge 1000-1250rpm for 7-10 minutes at 4ºC with the brake on. 
18. Decant the supernatant, disperse the cell pellet by flicking and re-suspend in a final volume of 10 ml 
chilled running buffer.  
19. Remove a 5 ul aliquot of cells for PBMC count and dilute 20 fold with 95 ul trypan blue in a 0.5 ml 
eppendorf. Use haemocytometer for counting the number of live cells (white). 
 
 
Plasma 
 
 
 
PBMC (peripheral blood mononuclear 
cells) 
 
 
Ficoll/histopaque 1077 
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Total cell number:  
Number counted x Dilution factor x 104 x Total volume of the cell suspension 
20. Aliquot 20 ul for FACS analysis into 0.5 ml eppendorf labelled with 8p (unstained), 8p (CD8-APC), 8p 
(CD3-PE) and 8p (double stained) and keep on ice. 
21. Centrifuge the PBMC at 1250 rpm for 7 minutes at 4ºC.  
22. Decant supernatant and resuspend the pellet in 80 µl running buffer per 107 cells. [total no. cells / 107 
= ___ x 80 ul = ___ ul running buffer].  
23. Add 20 µl of CD8 microbeads per 107 cells. [volume running buffer/4 = ul microbeads].  
24. Incubate in the fridge for 20-30 minutes.  
25. After incubation add up to 5 ml of running buffer. 
26. Centrifuge 1250 rpm for 7 minutes at 4ºC.  
27. Decant supernatant and re-suspend the cell pellet in 600 µl running buffer.  
28. Place CD8+ labelled cells on the autoMACS and place clean 15 ml Falcon tubes under the positive 
[CD8+ tube] and negative [CD8- tube] outlet ports.  
29. Select cell separation programme. Positive fraction eluted will be CD8+ T cells and the negative fraction 
eluted is the CD8- unlabelled flow through. 
30. Run quickRINSE programme to clean autoMACS prior to next purification. 
31. Remove a 5 ul aliquot of CD8- cells and dilute 20 fold with 95ul trypan blue in a 0.5 ml eppendorf and 
count the live cells using the haemocytometer. 
32. Take 5 ul of positive fraction and dilute 2 fold with trypan blue, then count the live cells. 
33. Optional: Remove 20ul aliquot of both the positive and negative fraction (8+, 8-) and keep on ice until 
the end of this protocol for FACS. 
34. Centrifuge the cell suspension at 1250 rpm for 7mins at 4ºC.  
35. Proceed to RNA preparation. 
Granulocyte Separation 
36. After 30 mins on ice, centrifuge the tube of lysed red blood cells at 1250 rpm for 7 mins at 4ºC, with 
brake.  
37. Decant supernatant into virkon jar and disperse the pellet by flicking. 
38. Add 25 ml chilled red cell lysis buffer to each tube and mix well by inversion. 
39. Centrifuge 1250 rpm for 7 minutes at 4ºC. 
40. Decant the supernatant into virkon jar and disperse the cell pellet.  
41. Re-suspend each pellet in 25 ml chilled rinsing buffer. (Pool contents of both tubes). 
42. Centrifuge 1250 rpm for 7 minutes at 4ºC. 
43. Decant the supernatant into virkon jar and disperse the cell pellet by flicking. 
44. Re-suspend the pellet in 10 ml chilled running buffer. 
45. Remove a 5 ul aliquot of cells for granulocyte count and dilute 20 fold with 95 ul trypan blue in a 0.5 
ml eppendorf: use haemocytometer for counting the number of live cells (white). 
Total cell number:  
Number counted x Dilution factor x 104 x Total volume of the cell suspension 
 204 
46. Collect 20 ul aliquot for FACS analysis in tubes labelled with: Granulocytes (unstained), 
Granulocytes (CD15-FITC), Granulocytes (CD16-PE), Granulocytes (double stained). 
47. Centrifuge granulocytes at 1250 rpm for 7 mins at 4ºC. 
48. Proceed to RNA preparation. 
49. Decant supernatant and disperse the cell pellet in appropriate volume of RLT Plus buffer to each 
sample: 
Note: Add 10ul of β–ME per 1ml of RLT Plus; make fresh each time 
300  μl  <5x106 cells  
600 μl – 5x106 – 1x107 cells  
50. Pipette thoroughly to mix and load samples onto Qiagen QIAshredder spin columns (maximum 700 
μl). Centrifuge for 2 minutes at 14800 rpm. 
51. Discard the column and store the flow-through at -80ºC for RNA/DNA extraction. 
B) Sample Preparation for FACS 
52. Add 200 ul of running buffer to each cell fraction and transfer to appropriately labelled FACS tubes. 
53. Centrifuge the samples at 1250 rpm for 7mins at 4ºC.  
54. Decant supernatant, disperse the cell pellet by dragging tubes along hedgehog holder and add the 
appropriate antibody cocktail to each tube (see table below). [Antibodies stored @ 4°, in dark.  Keep 
on ice whilst using.] 
 
Tube Cells Antibodies (20 μl of each) 
1 Unstained 8p -                             -     
2 CD8p (CD8-APC) - CD8-APC       
3 CD8p (CD3-PE) CD3-PE - 
4 CD8p(double stained CD3-PE CD8-APC       
5 CD8 +ve CD3-PE CD8-APC       
6 CD8 -ve CD3-PE CD8-APC       
7 Unstained  granulocytes - - 
8 Granulocytes(CD15-FITC), CD15-FITC - 
9 Granulocytes (CD16-PE) - CD16-PE        
10 Granulocytes (double stained) CD15-FITC CD16-PE        
 
[One antibody is a selection marker specific for the cell type, the second antibody is used to check the 
purity of selected cells, i.e. it is non-specific and reacts with other cell types] 
 
55. Incubate for 20 minutes at 4ºC. 
56. Add 1 ml running buffer to each tube and centrifuge at 1250 rpm for 7mins at 4ºC. [Washes off excess 
antibody] 
57. Decant the supernatant, disperse the cell pellet and add 300µl of FACs fixing buffer to each tube, 
cover with para-film and store in the fridge until ready to use. 
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Appendix 4. Paediatric Crohn's Disease Activity Index (PCDAI) 34 
 
ITEM POINTS 
Abdominal pain 
None 0 
Mild (brief episodes, not interfering with activities) 5 
Moderate/severe (frequent or persistent, affecting with activities) 10 
Stools  
0-1 liquid stools, no blood 0 
2-5 liquid or up to 2 semi-formed with small blood 5 
Gross bleeding, >6 liquid stools or nocturnal diarrhoea  10 
Patient functioning, general well-being (Recall, 1 week)  
No limitation of activities, well 0 
Occasional difficulties in maintaining age appropriate activities, below par 5 
Frequent limitation of activities, very poor 10 
EXAMINATION 
Weight  
Weight gain or voluntary weight loss 0 
Involuntary weight loss 1-9% 5 
Weight loss >10% 10 
Height  
< 1 channel decrease (or height velocity > -SD) 0 
> 1<2 channel decrease (or height velocity < -1SD> -2SD) 5 
> 2 channel decrease (or height velocity < -2SD) 10 
Abdomen  
No tenderness, no mass 0 
Tenderness, or mass without tenderness 5 
Tenderness, involuntary guarding, definite mass 10 
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Peri-rectal disease  
None, asymptomatic tags 0  
1-2 indolent fistula, scant drainage, tenderness of abscess 5 
Active fistula, drainage, tenderness or abscess 10 
Extra-intestinal manifestations  
Fever > 38.5 x 3 days in week, arthritis, uveitis, erythema nodosum, or pyoderma gangrenosum 
None 0 
One 5 
Two 10 
LABORATORY 
Hct (%) 
< 10yrs: > 33 0; 28-33 5; < 28 10 
11-14 (male): > 35 0; 30-34 5; < 30 10 
15-19 (male): > 37 0; 32-36 5; < 32 10 
11-19 (female): > 37 0; 32-36 5; < 32 10 
ESR (mm/hr)  
< 20 0 
20-50 2.5 
> 50 5 
Albumin (g/L)  
>35 0 
31-34 5 
<30 10 
 
Appendix 4. Legend 
Disease severity is defined by the following scores: 
• severe: 40 or above 
• moderate: 30-39 
• mild: 10-29 
• remission (disease not active): below 10 
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Appendix 5. Paediatric Ulcerative Colitis Activity Index (PUCAI) 35 
Item Category/Points 
Abdominal pain 
No pain = 0 
Pain can be ignored = 5 
Pain cannot be ignored = 10 
Rectal bleeding 
None = 0 
Small amount only, in less than 50% of stools = 10 
Small amount with most stools =20 
Large amount (50% of the stool content) = 30 
Stool consistency of most stools 
Formed = 0 
Partially formed = 5 
Completely unformed = 10 
Number of stools per 24 hours 
0-2 = 0 points 
3-5 = 5 points 
6-8 = 10 points 
>8 = 15 points 
Nocturnal stools (any episode 
causing wakening) 
no = 0 points 
yes = 10 points 
Activity Level 
No limitation of activity = 0 
Occasional limitation of activity = 5 
Severe restricted activity = 10 
 Sum of PUCAI (0-85) 
 
Appendix 5. Legend 
Disease severity is defined by the following scores: 
• severe: 65 or above; 
• moderate: 35-64; 
• mild: 10-34; 
• remission (disease not active): below 10. 
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Appendix 6. Paris Classification for Paediatric IBD 13 
 
Crohn's Disease 
Age A1 
• A1a <10 years; 
• A1b >10 <17 years. 
Location (macroscopic only) 
• L1 distal 1/3 ileum, ileum +cecum 
• L2 colon 
• L3 ileocolon 
• L4a upper disease proximal to Treitz, L4b distal to Treitz  
Behaviour 
• B1 non stricturing non-penetrating 
• B2 stricturing 
• B3 penetrating 
• B2,3 both stricturing and penetrating 
Growth 
• G0 no evidence of growth delay 
• G1 growth delay 
Ulcerative Colitis 
Location (macroscopic only) 
• E1 Proctitis 
• E2 Left sided 
• E3 Extensive 
• E4 Pancolitis  
Disease activity • S0 Never Severe 
• S1 Severe at any time (PUCAI ≥ 65) 
 
Appendix 6. Legend 
PUCAI: Paediatric Ulcerative Colitis Activity Index (see Appendix 4) 
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Appendix 7. Power Calculations 
 
Patients were recruited in two consecutive phases, so the data was initially collected and analysed from a first 
group of 45 children (discovery cohort) and subsequently from a second group of 67 (validation).  
The group size of our validation cohort exceeded the 50 cases recommended as per power calculations 
performed on the preliminary data obtained by the discovery cohort. 
 
 
Figure A7. Power calculations to detect size of validation cohort based on preliminary results from the discovery 
cohort (n=45) 
 
Power calculations were performed using the package "pwr" on R bioconductor. 
The definition of power is the probability of detecting a specified effect at a specified significance level 169.  
“Specified effect” refers to the effect size which can be the result of an experimental manipulation or the 
strength of a relationship between 2 variables. This effect size is ‘specified’ because prior to the power analysis 
we should set the size of the effect we expect to see. The ‘probability of detecting’ it refers to the ability of a 
test to detect an effect of a specified size. The recommended power is generally 0.8 which means we have an 
80% chance of detecting an effect if one genuinely exists 169.  
The main output of a power analysis is the estimation of a sufficient sample size.  
For this study, we based on preliminary results from WGCNA in our discovery cohort (n=43). As explained 
above, WGCNA provides a measure of the correlation between modules (groups of genes with similar gene 
expression level) and clinical outcomes. Preliminary results from the WGCNA in our discovery cohort of 43 
children with IBD showed top correlation index between modules and outcomes around 0.5. Aiming to reach 
an ideal correlation index of 0.8 in a larger cohort, we used a delta of 0.3 (30%) in our settings. Power was 0.8 
and p-value < 0.05. 
As shown in Figure, the sample size estimated for our validation cohort was around 50 samples. 
 
